Improving patient selection for complex cardiac implantable electronic devices:Pathophysiological insights, biomarkers and cost effectiveness by Claridge, Simon Braham Leo
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Improving patient selection for complex cardiac implantable electronic devices
Pathophysiological insights, biomarkers and cost effectiveness
Claridge, Simon Braham Leo
Awarding institution:
King's College London
Download date: 05. Apr. 2019
 1 
IMPROVING PATIENT SELECTION FOR COMPLEX 
CARDIAC IMPLANTABLE ELECTRONIC DEVICES:  
 
PATHOPHYSIOLOGICAL INSIGHTS, BIOMARKERS 






LLB (Hons), MBBS (Hons), MRCP (UK) 
Department of Imaging Sciences & Biomedical Engineering 
King’s College London 
 



















Cardiac resynchronisation Therapy Devices (CRT) and Implantable Cardioverter 
Defibrillators (ICDs) are routinely implanted in heart failure patients and patients at 
risk of ventricular arrhythmias (VA).  Not all patients with CRT experience an 
improvement with symptoms and not all patients with an ICD receive an appropriate 
shock or therapy.  Improved patient selection for these devices would be beneficial 
and is the focus of this thesis with my investigations focusing on the underlying 
pathophysiological mechanisms of dyssynchronous heart failure, potential novel 
imaging biomarkers to predict outcomes from complex cardiac devices and also an 
analysis of the cost-effectiveness implications of improved patient selection. 
 
Recent research has suggested a role of improved coronary flow in patients who 
respond to CRT and also an improved haemodynamic response to left ventricular 
endocardial pacing.  We performed a prospective clinical study to assess whether left 
ventricular endocardial pacing improved coronary flow and a further sub-study to 
investigate the relationship between coronary flow and acute contractility.  
 
Our understanding of the role of myocardial fibrosis and scar in the pathogenesis of 
VA is evolving and it is now possible to assess both of these entities using cardiac 
magnetic resonance imaging (CMR). We performed a prospective study to determine 
whether CMR identification of fibrosis and scar could be used to predict VA in an 
ICD population specifically focusing of measures of myocardial fibrosis in patients 
with non-ischemic cardiomyopathy and measure of myocardial scar and peri-infarct 
heterogeneity (grayzone) in patients with ischemic cardiomyopathy.  This study 
demonstrated for the first time that T1 mapping (a marker of fibrosis) was a specific 
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markers of risk in the non-ischemic group whereas grayzone predicted risk in the 
ischemic group. 
 
Finally, I used published data to demonstrate the cost-effectiveness of a risk 
stratification tool which determines whether CRT defibrillator patients should be 
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Chapter 1 Background 
1.1 Cardiovascular disease and heart failure  
 
Cardiovascular disease is the second most common cause of death in the United 
Kingdom (UK) accounting for over 150,000 deaths in 2015 with a total cost to the 
UK of >4,000,000,000 pounds per year.1 Cardiovascular disease can manifest in 
many ways including coronary artery disease, cerebrovascular disease, valvular heart 
disease, electrophysiological abnormalities and intrinsic heart muscle problems.   
 
The endpoint of many of these conditions is heart failure or “the heart failure 
syndrome”.  Heart failure can be described as a defect in heart function, which leads 
to a rise in atrial pressure leading to symptoms of breathlessness (if the left side of the 
heart is affected) or swelling in the legs and abdomen (if the right side of the heart is 
affected).   Breathlessness is typically assessed using the New York Heart Association 
Classification (see Figure 1). 
 




Class I No limitation on physical activity. 
Ordinary physical activity does not cause 
breathlessness fatigue or palpitations 
Class II Slight limitation of physical activity. 
Comfortable at rest but ordinary physical 
activity results in undue breathlessness, 
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fatigue or palpitations 
Class III Marked limitation of physical activity. 
Comfortable at rest but less than ordinary 
physical activity results in undue 
breathlessness, fatigue or palpitations 
Class IV Unable to carry on physical activity 
without discomfort. Symptoms at rest can 
be present. If any physical activity is 
undertaken, discomfort is increased. 
 
The syndrome can be further classified into patients with a reduction in the left 
ventricular pumping function of the heart- Heart failure with reduced ejection 
fraction-“HF-REF” and patients with preserved contraction but in whom increased 
pressures are required to fill the left ventricle- Heart failure with preserved ejection 
fraction- “HF-PEF”. 
 
It is estimated that over 900,000 people in the UK suffer from heart failure.2 With 
optimum treatment, the annual mortality from HF-REF is estimated to be in the 
region of 5-10%.2 Targets for the treatment of heart failure have been identified as our 
understanding of the pathophysiology has evolved with ACE inhibitors, aldosterone 
receptor antagonists, cardioselective betablockers, If channel blockers and most 
recently neprilysin inhibitors all forming part of an evidence-based medical 









Despite the undoubted role these medications play in improving mortality and 
morbidity in HF-REF patients, there remains significant mortality associated with the 
heart failure syndrome.  The two commonest modes of death are sudden cardiac death 
as a result of ventricular arrhythmia (VA)) and chronic cardiogenic shock as a result 
of pump failure.  Alongside, this evolution in medical therapy for HF-REF, two 
medical devices have been developed in the last 30 years which have also 
demonstrated mortality benefits, targeting the risk of sudden death and pump failure 
separately although they are often prescribed together in patients and can be 
implanted in a single device.  The two devices are Implantable Cardioverter 
Defibrillators (ICDs) and Cardiac Resynchronisation Therapy (CRT). 
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1.1.1 Development of CRT and evidence base 
 
Heart failure patients particularly those with HFREF often have abnormal electrical 
activation of the heart.  This can manifest as atrial arrhythmias such as atrial 
fibrillation and atrial flutter, conduction abnormalities across the atrio-ventricular 
node, ventricular ectopy and ventricular dyssynchrony.  Each of these abnormalities 
has the potential to cause unco-ordinated contraction of the heart resulting in impaired 
cardiac output and worsening heart failure.  This reduced cardiac output results in 
upregulation of neurohumoral activation, adverse remodelling and creates a vicious, 
downward spiralling circle. 
 
Ventricular dyssynchrony specifically results in the contraction of different parts of 
the ventricle at different times, typically resulting in the prolongation of electrical 
activation across the ventricle to >120ms.  Three typical forms of ventricular 
dyssynchrony are described, left bundle branch block (LBBB), right bundle branch 
block (RBBB) and non-specific interventricular conduction defects.  This delay 
represents a potential target for therapy with the aim being to reduce electrical 
activation of the ventricles back to normal by stimulating the ventricles from different 
sites simultaneously.  This was first attempted acutely by Cazeau et al and chronically 
by Daubert et al in 1998 who succeeded in obtaining permanent biventricular pacing 
in 35 patients using a normal right ventricular lead placed in the right ventricular 
endocardium and a left ventricular lead placed via the coronary sinus into a branch of 
the left sided coronary venous system. 8,9 From these first experimental uses, there 
have now been several large randomised controlled trials that have shown CRT 
reduces mortality in HFREF patients of different NYHA classes and is now 
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considered a standard treatment offered to patients with heart failure and abnormal 
electrical ventricular activation. 10,11 
 
1.1.2 CRT outcomes and non-response 
 
Despite the positive results of the CRT trials, it was clear that not all patients in the 
study populations benefitted from CRT implantation.   
 
With regard to those patients who did not seem to improve with CRT, the term ‘non-
responder’ was coined which in turn led to a large volume of research into how to 
select likely non-responders prior to implant and how to turn non-responders into 
responders.   The definition of response varies with some authors referring to an 
improvement in NYHA symptoms, others to a  >15% reduction in Left Ventricular 
End Systolic Volume and others using a combination of these criteria or variations of 
these metrics.  A reduction in LVESV has been shown to better predict long term 
outcome following CRT than reported changes in symptoms and is the metric used to 
determine response in this thesis.12 
 
1.1.2.1 Selecting likely responders to CRT in advance 
 
Research initially focused on whether advanced imaging (specifically transthoracic 
echocardiography measures) might be able to help predict responders to CRT and 
small, single centre studies initially suggested that echocardiography may be able to 
select patients with mechanical dyssynchrony who might better respond to CRT. 13-16.  
Disappointingly however, the TARGET trial demonstrated that when these indices 
were examined in a large multi-centre cohort then the previously achieved results 
were not reproducible. 17,18  
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This disappointment led in turn to further investigation of the pathophysiological 
effects of dyssynchronous heart failure and the physiological effects of CRT. It 
became clear that dyssynchronous heart failure led to changes in coronary flow, 
metabolism and even gene expression and that CRT had the potential to reverse some 
of these changes (see Figure 3).19-22  
 





1.1.2.2 Turning non-responders into responders 
 
Whilst it is evident that some patients do not get better with CRT, as noted above, the 
definition of non-response is variable and thus the proportion of patients who do not 
respond to CRT varies depending upon the definition employed. When using quality 
of life assessment scores the non-response rate has been shown to be approximately 
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30-35% whereas when a harder endpoint such as reduction in left ventricular end 
systolic volume >15% has been used as the measure the number of non-responders is 
nearer 50%.24-26 Regardless of the definition used, the cohort of patients who do not 
benefit from CRT represents at least a significant minority of those who are implanted 
with the device.  This has lead to the development of literature assessing the reasons 
for poor outcomes in CRT and suggested strategies for optimising non-responders 
(see Error! Reference source not found.).27 
 




1.1.2.3 Left ventricular endocardial pacing 
 
The identification of patients who fare poorly with CRT particularly those who may 
have either a “suboptimal lead position” as noted in Error! Reference source not 
found. has led investigators to consider different ways to deliver CRT in patients who 
are not responding. 
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Potential strategies that have been attempted include stimulation from several points 
in the ventricle –“multi site pacing” and pacing from inside the left ventricle rather 
than from the epicardial coronary veins – “endocardial” pacing. 28,29 Endocardial 
pacing is particularly attractive in that theoretically the left ventricular lead position is 
not constrained by the coronary venous anatomy allowing access to the latest 
activating segment of the heart, avoidance of myocardial scar and theoretical early 
access to the Purkinje network.30,31 Acute improvements of ventricular function have 
been demonstrated with endocardial pacing over and above standard CRT and a large 
case series has reported positive findings in non-responders and patients in whom 
implantation of a conventional LV lead proved impossible.29,32  Nonetheless the 
mechanism by which endocardial pacing exerts its apparent benefits is unclear. 
 
1.1.3 Changes in coronary flow and perfusion with CRT 
 
As noted above, this failure to easily identify non-responders has led to increasing 
interest in the pathophysiological mechanisms that underlie electrical and mechanical 
dyssynchrony in heart failure. One aspect of this has been a renewal in interest in the 
importance of myocardial perfusion to CRT response and its relationship with any 
concomitant metabolic abnormalities.  Previous studies suggested CRT offered an 
increase in global contractility without an increase in overall myocardial work or 
oxygen consumption.33 However a recent study has suggested that myocardial oxygen 
consumption does increase with CRT but that the corresponding increase in 
contractility is relatively much greater resulting in an improvement in overall 
myocardial efficiency. 34 Furthermore, experimental work in the canine model 
suggests that response to CRT is dependent on a minimal myocardial perfusion. 
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35Perfusion below this threshold, which lies within pathophysiological levels seen in 
the clinical setting, seems to preclude a favourable response to CRT. 
 
Thus, the role of myocardial perfusion in CRT appears to be a relevant area of inquiry 
and one of the elements that needs to be understood in the search for accurate criteria to 
predict CRT response.  Furthermore increasingly accurate descriptions of metabolic 
changes associated with heart failure and electromechanical dyssynchrony are 
beginning to show promise in the prediction of non-response. 
 
1.1.3.1 Effect of ventricular dyssynchrony on myocardial perfusion and coronary 
flow 
 
There has been a wealth of research into the assessment of the coronary circulation 
and myocardial perfusion in patients with LBBB. 36 This is due to the particularly 
marked positive response of these patients to CRT and also the significant historical 
interest in “false positive” non-invasive tests for inducible ischaemia in this cohort.  
LBBB represents a delay in electrical and accordingly mechanical activation of the 
left ventricle resulting in inter- and intraventricular dyssynchrony.  
 
Early work by Delhaas et al in a canine model paced from different ventricular sites, 
demonstrated significantly reduced regional oxygen uptake and regional blood flow in 
early activated areas of myocardium compared with late activated areas. 37 This was 
refined in a canine model,  where septal hypoperfusion was linked with a reduction in 
the systolic circumferential shortening following left bundle branch ablation.38 The 
model also demonstrated an increase in myocardial blood flow to the lateral wall in 
conjunction with an increase in systolic circumferential shortening in that region.  
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These findings suggest that the reduction in myocardial blood flow to the septum may 
be a result of reduced septal workload and conversely that the increase in myocardial 
blood flow to the lateral wall is a result of an increased workload.  Such findings 
suggest a physiological rather than pathological response.  Further work by Vernooy 
et al demonstrated that these regional differences in myocardial bloodflow 
disappeared following the application of CRT.39  
 
Studies that assessed the effects of ventricular electromechanical dyssynchrony on 
myocardial perfusion and metabolism in man have largely obtained data from nuclear 
imaging. Initial investigation of patients with LBBB suggested that there was relative 
hypoperfusion in the septum compared with the lateral wall of the left ventricle even 
in patients with normal coronary arteries and these findings have been replicated on 
many occasions. 40,41 
 
More recent quantitative research by Koefli et al has demonstrated an increase in 
global myocardial blood flow during rest and exercise in presumed non-ischaemic 
patients with LBBB when compared with patients without electrical dyssynchrony. 42  
This increase in myocardial perfusion, particularly in the lateral wall during exercise, 
accords more with Delhaas’ and Vernooy’s findings in the canine model and may be a 
reflection of increased myocardial oxygen demand due to inefficient cardiac 
mechano-energetics induced by dyssynchronous electrical activation. The rationale 
for this is that, in a normal LV, all myocardial segments are activated almost 
simultaneously and contract synchronously. This results in both septal and lateral 
annuli being pulled towards the stationary LV apex. However, in LBBB, the septum 
is activated first and while it is developing a contractile force and shortening, the 
contralateral wall is passive. This exerts a pulling effect on the latent opposite wall.  
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The combination of unloaded contraction of the septum, stretching the lateral wall, 
followed by delayed lateral wall contraction, which then stretches the septum, leads to 
an overall greater workload, particularly for the lateral wall.  This is reversed when 
CRT is applied resulting in homogenisation of work across the ventricle. 
 
Koepfli’s study also demonstrated reversible relative hyperperfusion in the lateral 
wall of patients with reversible LV dyssynchrony during right ventricular (RV) pacing 
compared with their intrinsic rhythm. Thus rather than LBBB causing septal 
hypoperfusion it is possible that LBBB causes lateral wall hyperperfusion.   
 
Koepfli studied “spontaneous” LBBB patients and makes no reference to the patients’ 
LV systolic function.   This limits extrapolation of these findings to the CRT heart 
failure population.  For patients who have developed LV impairment as a result of 
chronically high percentages of right ventricular pacing are likely to have undergone 
cellular and metabolic changes not found in those with LBBB without heart failure.43 
Indeed, longer term RV apical pacing has been shown to result in myocardial 
perfusion defects in variable locations within the ventricle. 44The incidence and size 
of these perfusion defects increases with time.  They are associated with apical wall 
motion abnormalities and a reduction in left ventricular ejection fraction.    
 
Koepfli’s work is alone in studies on man suggesting that there is lateral wall 
hyperperfusion rather than septal hypoperfusion.  In spite of the above criticisms, this 
quantitative assessment of both coronary flow and myocardial perfusion suggesting 
lateral wall hyperperfusion on exertion offers a different explanation to the septal 
hypoperfusion hypothesis examined above. 
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The theory that dyssynchrony may alter regional myocardial work is supported by 
Masci et al. who found using Positron Emission Tomography (PET) that patients with 
LBBB and reduced ejection fraction had a higher myocardial glucose metabolism in 
the lateral wall compared with the septum when compared with a group of non-
dyssynchronous patients with non-ischaemic cardiomyopathy.45 This suggests that a 
heterogeneous shift in the LV regional workload due to dyssynchrony results in 
alterations in the regional myocardial metabolic demand. The extra metabolic load as 
a result of dyssynchronous LV contraction can in theory lead to higher demand on 
global myocardial perfusion.  However, Masci found no consistent changes in 
myocardial perfusion to either confirm or refute this theory.   
 
Skalidis et al. demonstrated, in an invasive setting, that the time to maximum peak 
diastolic flow velocity was significantly longer in the left anterior descending (LAD) 
coronary artery of patients with LBBB and perfusion defects compared with normal 
subjects. 46 This observation coupled with the associated reduction in coronary flow 
reserve (CFR) suggests that dyssynchrony can have a deleterious effect on the 
myocardial microvascular circulation.  Interestingly, Koepfli also noted a reduction in 
the CFR in the septum of patients with LBBB.  Skalidis et al postulated that an 
increase in early diastolic compressive resistance resulting from delayed ventricular 
relaxation in LV dyssynchrony resulted in an impairment of early diastolic blood flow 
in the LAD. The authors further demonstrated that CFR was similarly reduced in 
patients with LBBB induced by RV pacing. 47This impairment of CFR seems to 
suggest that septal perfusion defects are not a physiological response to reduced 
demand but a pathophysiological adaptation. 
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Most recently Ogano et al have demonstrated in a non-ischaemic group of patients the 
presence of septal perfusion defects in 19/26 patients with LBBB. 41 Following the 
implant of a biventricular pacemaker, an improvement in the septal perfusion defect 
correlated with a reduction in left ventricular end systolic volume. 
 
As noted above, much of the perfusion data is taken from semi-quantitative analysis 
of SPECT.   This technique assumes that there is equal systolic wall thickening across 
the ventricle; however in LBBB there is reduced septal systolic wall thickening.   This 
means that SPECT assessment of septal perfusion in LBBB should be interpreted 
cautiously as there is the risk of partial-volume effects mimicking hypoperfused 
myocardium.  Nowak et al demonstrated this elegantly, comparing Single Photon 
Emission Computed Tomography (SPECT) with Positron Emission Tomography 
(PET) perfusion of LBBB patients.48 They found that the corrected myocardial blood 
flow using PET was homogenous across the LBBB ventricle compared with the 
heterogenous perfusion found using SPECT.  Of note, the heterogeneities tended to 
show septal hypoperfusion. 
 
It is tempting to suggest that all the noted perfusion defects in LBBB are the result of 
this issue.  However, soon after Nowak’s study had been published, Vernooy et al 
reported experimental data using a canine model that had undergone LBBB ablation. 
Using microspheres, (the gold standard of perfusion quantification), the group 
demonstrated a 17 +/- 16% reduction in septal myocardial blood flow and a 18 +/- 
12% increase in the lateral wall myocardial blood flow  from baseline.  This shift in 
blood flow was reversed following the application of CRT. 
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These data suggest that dyssynchronous electrical activation leads to altered coronary 
flow patterns and subsequent changes in perfusion and metabolism which may be 
deleterious to cardiac function.  It is however unclear whether the well described 
heterogeneity in perfusion reflects hypoperfusion of the septum or hyperperfusion of 
the lateral wall (see Table 1). This assessment is further complicated by the possibility 
that the assumptions of SPECT imaging render it a poor modality to assess perfusion 
in LBBB patients (see Figure 5). It is suggested that the well-described reduction in 
CFR in the septum in man as noted by Skalidis et al reflects a pathological rather than 
physiological down regulation of septal coronary flow as one would expect a 






















Table 1- Summary of studies investigating blood flow and perfusion with 
dyssynchronous heart failure 
 
 N= Study model Method FDG uptake Global MBF Regional MBF MBFR CFV/ CFR 
Masci13 
(2010) 
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increased  
perfusion than 
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with 
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Skalidis14 
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24 NICM (LBBB) 
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N/A N/A Time to diastolic  
Vmax > in Group 1 than  
Group 2 and controls 
 
 
Group 1 lower CFR < 
Group 2 < Control group 
Skalidis15 
(2001) 
22 RV paced (14) 












N/A CFV lower in paced 
patients. 
If perfusion defect, further 
reduction in CFR 
Nielsen 30 AAI (15) vs PET N/A DDD pacing DDD pacing N/A N/A 
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and inferior flow 
 
The above table summarises the findings of the key studies investigating myocardial perfusion and coronary 
physiology in CRT patients.    
Abbreviations: CFR- coronary flow reserve, CFV- coronary flow velocity, CMR- cardiac magnetic resonance imaging, 
ICM- ischaemic cardiomyopathy, Inv,- Invasive study, MBF- myocardial blood flow, MBFR- myocardial blood flow 
reserve, NICM- non-ischaemic cardiomyopathy, N/A- not applicable 
 
Figure 5- Panel A demonstrates SPECT imaging of LBBB. Panel B shows changes 






1.1.3.2  Effect of CRT on coronary flow and myocardial perfusion 
 
CRT achieves “resynchronisation” via atrial coordinated synchronised pacing of the 
right and left ventricles. The LV lead is usually placed via the coronary sinus in either 
a lateral or posterolateral coronary vein. 
 32 
Studies using PET to assess myocardial perfusion suggest that CRT does not 
increase global resting myocardial blood flow. 49-52 It may however result in 
regional changes in myocardial perfusion and oxygen demand. 41,53,54 These 
changes manifest as a reduction in myocardial oxygen demand and perfusion to the 
lateral wall with an equivalent increase in these indices in the septum with CRT.  
However, such regional changes in perfusion in response to CRT have not been 
shown consistently.48  Further to this, it is unclear whether the homogenisation of 
blood flow to the septum and away from the lateral wall represents the correction of 
pathophysiological changes in coronary flow or simply a physiological response to 
the fact that the septum works harder and the lateral wall less hard once CRT is 
applied.   The difficulty in comparing the many studies referenced above is a result 
of the small number of patients studied in each protocol and the different 


















Table 2- Summary of studies assessing the effect of CRT on coronary bloodflow, 
myocardial perfusion and metabolism 
 
CRT N= ICM/ 
NCM 
























10 0/10 PET No change No change N/A N/A No change N/A N/A 8 months post implant 
Neri17 
(2003) 
8 0/8 PET N/A No change No change N/A N/A N/A Homogenisation 
of  FDG uptake 
Pre and 3 weeks post implant 
Nielsen18 
(2002) 
14 7/14 PET N/A No change No change N/A N/A N/A N/A Comparison of acute pacing  




14 0/14 PET No change  No change No change No change N/A N/A Homogenisation 
of  FDG uptake 














ICM: similar trend  
N/a  N/A N/A All acute responders. 
PET performed at pre and 4 
months post implant 
Fang23 
(2012) 
29 0/29 Echo N/A N/A N/A N/A N/A ñ 
CFV 




14 0/14 PET  N/A No change Homogenises 
Lateral wall to 
septum 
N/A Increased  N/A N/A Pre and 3 months post CRT insertion 
Kyriacou25 
(2012) 
10 3/10 Inv N/A N/A N/A N/A N/A ñ 
CFV 
N/A Associated with increase in 




20 20/20 Inv N/A N/A N/A N/A N/A ñ 
CFV 
N/A Increase noted in responders 
Ukkonen26 
(2003) 
8 6/8 PET No change N/A N/A Increased in 
septum  








N/A  N/A N/A N/A SPECT pre implant and at 6 
Months 
  
CFR- coronary flow reserve, CFV- coronary flow velocity, CMR- cardiac magnetic resonance 
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imaging, ICM- ischaemic cardiomyopathy, Inv,- Invasive study, MBF- myocardial blood flow, 
MBFR- myocardial blood flow reserve, NCM- non-ischaemic cardiomyopathy 
 
Studies using transthoracic Doppler echocardiography demonstrated an increase in 
LAD flow during resynchronisation pacing and were replicated by Fang et al who 
demonstrated increased regional LAD flow in responders to CRT when paced 
biventricularly compared with RV pacing or their intrinsic rhythm. 54,55Fang also 
replicated Skalidis’ finding of attenuation of the LAD diastolic flow during 
dyssynchrony and further showed that the LAD flow was corrected during acute 
resynchronisation. 
 
The effect of CRT, on the microvascular circulation measured by myocardial flow 
reserve or coronary flow reserve (in the absence of epicardial artery stenoses) is 
unclear.   Using PET, Knaapen et al.  demonstrated a significant increase in the 
myocardial flow reserve with CRT  however Sundell et al demonstrated no change in 
the flow reserve. 53,56 This divergence may be partly explained by the different patient 
population in the studies.  In Knaapen’s study, 7 out 16 patients had ischaemic 
cardiomyopathy whereas the study of Sundell included a majority of patients with 
non-ischaemic dilated cardiomyopathy.  Also, Sundell studied acute changes in blood 
flow in different pacing regimens in chronically implanted CRT patients as opposed 
to Knaapen who compared changes in blood flow before and after 3 months of CRT.    
There is limited invasive data available assessing the acute effect of CRT on coronary 
flow.  Nelson et al detected a non-significant reduction in coronary flow despite 
improved systolic function with CRT although this measure was not controlled for 
different heart rates. 33 Nelson observed that an improvement in systolic function 
occurred with a reduction in myocardial oxygen consumption.  Conversely, during 
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administration of dobutamine to improve left ventricular contractility to the same 
extent as CRT, a significant increase in myocardial oxygen demand and extraction 
was seen.  These findings provided a biologically plausible explanation to both the 
success of CRT as a treatment and the failure of positively inotropic agents to 
improve outcomes in heart failure patients.   
The findings of this study have recently been refined by Kyriacou et al who compared 
the LV pressure generated in intrinsic LBBB with biventricular pacing at various 
atrio-ventricular timings.34  The authors found that biventricular pacing actually 
increased myocardial oxygen consumption but that the concomitant increase in 
cardiac work was proportionately 80% greater; thus there was greater myocardial 
efficiency.  Of note, Kyriacou’s study had a mix of patients with an ischaemic and 
non-ischaemic substrate whereas Nelson’s subjects were all non-ischaemic.  
Furthermore, Nelson allowed patients’ heart rate to vary and then corrected for the 
variation between intrinsic rhythm and biventricular pacing.  This has the advantage 
of being more physiological than atrial pacing above the sinus rate as biventricular 
pacing effects sympathetic activity and thus heart rate.  In contrast Kyriacou paced 
patients at 100bpm avoiding the need for post hoc correction of the data, thus 
allowing “per beat” assessment of myocardial oxygen consumption.  
The finding that CRT may increase myocardial oxygen consumption has important 
mechanistic and clinical ramifications implying that response to CRT relies, at least in 
part, on there being a means by which oxygen delivery can be increased or more 
efficiently extracted.   This accords with recent work in a canine model in which 
biventricular pacing was unable to acutely increase LV contractility at lower coronary 
perfusion rates suggesting there is a minimum perfusion rate required to obtain an 
increase in contractility. 35This threshold was within the pathophysiological range 
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found in vivo.  The improvement in LV contractility above the threshold was however 
independent of any increases in regional coronary flow observed with biventricular 
pacing. 
Deftereos et al. found that in patients with ischaemic cardiomyopathy, CRT is 
associated with higher CFRs when compared with RV pacing alone. 57Interestingly, 
this improvement in CFR was almost exclusively observed in responders to CRT. 
This result coupled with previously noted observations by Skalidis implicates the 
microvascular circulation in the deleterious effect of LV dyssynchrony and supports 
the hypothesis that CRT may be able to reverse this.     
 
It is therefore unclear whether the well-described changes in blood flow in response to 
CRT relate to changes in perfusion per se or merely represent the mechanical sequelae 
of restoration of a more physiological activation pattern.  Wave intensity analysis of 
simultaneously acquired coronary flow and pressure may provide further insights into 
the effects of CRT on coronary blood flow and the relationship between coronary 
blood flow and the haemodynamic effects of CRT. 
 
 




Wave intensity analysis is an area of physics that first developed in the field of gas 
dynamics and jet engines after the Second World War.  It has subsequently been 
successfully applied to the cardiovascular system to describe the energies that 
determine blood flow in the human body.58,59 
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1.1.4.2 Breaking down waves into constituent components 
 
For the purpose of wave intensity calculations, arteries are treated as 1 dimensional 
long thin tubes.  Wave intensity assumes laminar flow across the entire cross-section 
of the artery and is ill-suited for assessment of sections of the artery with unequal or  
pathological wall stress such as arterial bifurcations or areas of stenosis or occlusion. 
 
Generally, waves have been by described by use of a Fourier decomposition which 
treats the measured waveform as the summation of many different waves at different 
frequencies and amplitudes.  This is excellently demonstrated in Figure 6 by Parker et 
al taken from the website. (www.bg.ic.ac.uk/research/k.parker/wave_intensity_web 
)60  
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Figure 6- Fourier decomposition of aortic pressure waveform 
 
The top blue waveform is the aortic pressure waveform. The subsequent blue lines 
represent the different amplitude and frequency that superimpose to describe the 
aortic waveform.  Note this is only one of infinite ways to describe a waveform using 
the Fourier decomposition. 
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As can be clearly appreciated, the sinusoidal waveforms gives very little in the way of 
time sensitive information which is critical to the analysis of events occurring during 
a single heartbeat. As a result of this, wave intensity analysis calculations are 
described as successive wavefronts rather than as the sum of different repetitive 
sinusoidal wavefronts.  This allows clearer timing of events that summate to form the 
measured waveform and is limited only by one’s ability to measure changes in the 
wave form in the time domain ie the temporal resolution (see Figure 7). 
 
Wave intensity is defined as  
 
dI = dP. dU 
 
where dP is the change in pressure across a wavefront and dU is the change in 
velocity across a wavefront.. The unit of wave intensity is thus W/m2 
As a result of this, if waves are forward travelling they will have a positive sign 
whereas backward travelling will have a negative sign.  This makes it simple to 
determine both the direction of travel of a wave and also easy to determine the 
dominant wave at any given time point. 
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1.1.4.3 The relationship between dP and dU 
 
Changes in pressure and velocity are not independent of each other and this needs to 
be incorporated into wave intensity calculations in the cardiovascular system. Thus by 
using the water hammer equations, incorporating a measure of blood density and 
estimating wave speed, forward waves can be calculated using the equation: 
 
and backward waves can be calculated using a similar equation: 
 
 
where ρ is the density of blood and c is the wave speed. A full description of the 
mathematical underpinning of these equations to express wave energies in the human 
body can be found at www.bg.ic.ac.uk/research/k.parker/wave_intensity_web 
 
1.1.4.4 The sum of squares method to calculate wave speed 
 
Wave speed is calculated using the measured pressure and velocity waveforms.  The 
main assumption for wave intensity calculation and derived waves is the single point 
measure of local wave speed.   This is calculated using the sum of squares method.61  
This method of determining wave speed springs from the observation that using the 
incorrect speed results can result in wave intensities that either cancel each other out 




It is therefore necessary to find the value of c that results in the least wave intensity 
across a cardiac cycle. 
 





1.1.4.5 Wave intensity analysis in the coronary arteries 
 
Cardiac catheters have been developed which allow simultaneous acquisition of both 
pressure and flow data.  Using the equations above, it has therefore been possible to 
perform wave intensity analysis on coronary artery data using the sum of squares 
method to estimate the wave speed. 
 
Wave intensity analysis of coronary flow and pressure has shown coronary blood 
flow to be dependent upon up to 6 waves within the cardiac cycle (see Figure 8).  
Typically however, four waves are identified: Forward Compression Wave (FCW), 
Backward Expansion Wave (BEW), Forward expansion wave (FEW) and Backward 
Compression Wave (BCW).  The FCW and BEW are the largest and most 
reproducible.62 The FCW and BCW both occur in systole. The FCW is supposedly 
derived from LV contraction with the FCW pushing blood down the coronary artery 
via the aorta. The genesis of the BCW is controversial but an intramyocardial increase 
in pressure compressing the microvasculature during systole is often cited as the 
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origin. 63-65 With regard to diastole, the BEW is generated by relaxation of the 
ventricle resulting in suction of blood down the coronary arteries towards the 
microvasculature whereas the small FEW is generated at the aortic end of the artery. 
It has a decelerating effect on blood flow but this deceleration effect is minimal when 
compared with the suction effect of the BEW hence the significant increase in 
coronary flow seen in diastole (see Figure 8). 
 
Figure 8- Wave intensity of the coronary artery with coronary flow and pressure 
across a single heartbeat66 
 
 
Wave intensity analysis has been successfully used to investigate various disease 
states and had provided significant insight into the pathophysiology of conditions and 
the effect of treatments. 67-70 
 
Specifically, wave intensity analysis has been used to further characterise changes in 
coronary flow in the Left Main coronary artery (LMCA) with CRT.71 In this study, 
Kyriacou et al demonstrated an acute increase in LV contractility with biventricular 
pacing which was mirrored by an increase in coronary flow velocity, predominantly 
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due to an increase in the BEW, suggesting that improved relaxation of the ventricle 
resulted in improved coronary flow. 72 Following on from the previous discussion, in 
the absence of significant epicardial arterial disease or alteration to existing coronary 
disease, it can be presumed that this increase in coronary flow is either due to 
physiological auto-regulation mediated by changes in LV contraction and relaxation 
or due to a reduction in microvascular resistance secondary to these changes.   
 
If we are able to alter both coronary flow and contractility, wave intensity analysis 
should enable clarification as to whether coronary flow changes drive changes in 
contractility in CRT patients or vice versa. 
 
1.2 Cardiac MRI overview 
 
Cardiac MRI has evolved over the last 20 years to provide the gold standard in 
dynamic cardiac imaging.  This evolution has been driven not only by the quality of 
images derived which allow excellent reproducibility of measures but also the fact 
that unlike SPECT/ PET it does not rely on radioactive isotopes, unlike computed 
tomography it does not expose patients to ionising radiation and finally unlike 
echocardiography it does not rely on patients having adequate acoustic windows. 
 
Patients are placed in a magnetic field causing all the hydrogen ions (present in water 
and thus blood and tissue) to align in the direction of the magnetic field.  A further 
magnetic radiofrequency pulse (RF) is then delivered to excite and perturb the 
hydrogen ions.  This perturbation moves the hydrogen ions beyond the original 
magnetic field axis (z axis) with magnetisation directed in the x and y axes away from 
the original magnetic field.  When the RF pulse ends the hydrogen ions realign 
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themselves resulting in a measurable electric voltage which via a conductive field coil 
is processed into a greyscale magnetic resonance image. Application of a further 
magnetic field provides gradient in the x and y axes and allows 3 dimensional 
reconstruction of images. 
 
1.2.1 Left ventricular Functional Assessment 
 
CMR allows highly accurate assessment of ventricular size and function.  This can be 
very helpful in the case of patients with poor acoustic window on echocardiography 
when attempting to determine suitability for CRT implantation.  
 
1.2.2 Late gadolinium enhancement (LGE) 
 
Beyond simply assessing ventricular function, CMR is unique amongst imaging 
modalities in its ability to characterise myocardial tissue.  Gadolinium contrast has 
been used successfully in conjunction with CMR to identify areas of myocardial scar 
and also perfusion abnormalities.   
 
It was only in 1999 that this technique was histologically validated in the canine 
model but it now forms part of the standard clinical protocol in CMR centres 
worldwide.  The presence or absence of myocardial scar is potentially of importance 
when selecting patients for CRT.73,74 A detailed explanation of how LGE images are 
acquired in the studies presented here appears in the Methods section. 
 
By means of an overview however, gadolinium contrast tends to collect in the 
extracellular space rather than intracellularly and takes much longer (typically 15-30 
minutes) to wash out of the extracellular space than the healthy myocyte.  The 
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extracellular space is larger in areas of fibrosis and scar than in normal healthy tissue 
so gadolinium preferentially accumulates in this region.  These properties combine to 
provide a window of opportunity approximately 15 minutes after contrast injection 
when gadolinium will be located specifically in areas of fibrosis and scar. 
 
Specific CMR sequences are then used to take advantage of this window.  Inversion 
recovery sequences invert magnetisation with a 180 degree pulse and a subsequent 90 
degree RF pulse is then applied pushing any residual magnetisation into the transverse 
plane where it can be detected by the RF coil.  After the pulse ceases, the hydrogen 
ions begin to return to their normal state; this is termed “inversion recovery”. At a 
given inversion recovery time (TI) during this return, imaging acquisition can be 
performed to generate an image of the myocardium. In fact in clinical protocols, this 
acquisition is performed at many different TIs. This is called the Look-Locker 
sequence.  By acquiring data at different TI, a sequence of images is rapidly acquired 
which due to the pharmacokinetics of gadolinium and its varying concentrations in 
normal and abnormal myocardial tissue will provide differing degrees of contrast 
between the two (see Figure 9).  The TI with the best visible contrast between tissue 









Figure 9- Differing TI relaxation properties of normal and infarcted myocardium. 
 
 
The blue line shows the optimum TI where the contrast between healthy myocardium 
(black) and scarred myocardium (white) is most apparent.  This TI can now be used 
to collect short axis images of the entire myocardium 
 
 
1.2.3 CRT outcomes and LGE imaging 
 
One factor influencing the outcome of patients from CRT is the underlying cause of 
their heart failure with patients with an ischaemic aetiology faring far worse than 
those with a non-ischemic aetiology.75 CMR LGE imaging characterises scar such 
that it is usually possible to determine the aetiology of a patient’s cardiomyopathy 
based on the scar distribution and pattern.  Ischemic scar is subendocardial extending 
towards the epicardium as infarct size increases whereas non-ischemic scar tends to 
be more diffuse with a tendency to appear in the midwall of the septum. Thus CMR 
can help to not only determine the aetiology of heart failure but also to help predict 
potential response to CRT. 
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The presence of LGE on CMR has been shown to negatively effect outcome 
following CRT in both ischaemic and non-ischaemic patients.  In particular, the 
presence of LGE in the lateral wall of the LV (adjacent to where an LV lead would be 
positioned) has been shown to result in very poor outcomes from CRT and there is 
data to suggest that avoidance of scar when placing the LV lead is associated with 
improved CRT outcomes . 31,76-79  
 
1.2.4 T1 relaxation time, T1 mapping and CRT 
 
Myocardial T1 mapping is a relatively newly developed technique where the 
longitudinal proton relaxation time is measured after inversion.  Images are acquired 
at different TI for each voxel allowing a per voxel inversion recovery curve to be 
calculated based around the signal intensity at each TI (see Figure 10).  The T1 
relaxation time measures the time taken for the 63% of protons to realign themselves 
with the base magnetic field following termination of the RF pulse in the longitudinal 
axis.   
 
T1 mapping is a measure of the water content of tissue and has been histologically 
validated as a marker of diffuse myocardial fibrosis. 80-82   The technique enables true 
quantitative signal intensity analysis without the need for a subjective determination 
of the optimal inversion time, which potentially undermines the objectivity of LGE 




Figure 10 - Acquisition of T1 map using data recorded at eleven different TI to fit 






Modified Look-Locker Inversion Recovery Sequence (MOLLI) to calculate T1 
 
This technique uses a Modified Look-Locker Inversion Recovery Sequence 
(MOLLI) as depicted in  
Figure 10 with data from 11 different inversion recovery times from 3 different 
acquisitions merged into one dataset.  The three acquisitions are taken over 
typically 17 heartbeats.  The MOLLI sequence has a tendency to underestimate T1 
values, particularly at higher heart rates so a correction is required.(7-9) 
 
These data can be collected prior to the injection of gadolinium contrast (T1native) and 
at a predefined time after injection (T1post).  T1post has the same potential issues as 
LGE imaging in that it depends upon the pharmacokinetics of gadolinium in a patient 
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at any given moment, the dose given and the time delay between injection and data 
acquisition.   Other factors effecting the T1post measure because gadolinium is used 
include haematocrit leveland the renal clearance rate.  This limits intra and inter 
patient reproducibility of T1post.  
 
 
Extracellular volume (ECV) Quantification 
 
Quantification of the ECV has bee proposed as an alternative method to measure 
myocardial fibrosis.  This in theory should overcome issues relating to haematocrit in 
the T1post sequence by incorporating it with the following equation. Thus, 
 
ECV= (1 –	haematocrit) x ((1/ T1post(myocardium) –	1/ T1native(myocardium))/ (1/T1post(blood)–	1/ T1native(blood)) 
 
 
This equation calculates the ECV based upon the relative concentration of gadolinium 
in the myocardium relative to the blood and has been histologically validated in 
patients with both hypertrophic cardiomyopathy aortic stenosis.{Flett:2010eh} 
However, it requires a low dose infusion of gadolinium post intravenous bolus to 
achieve a dynamic steady state ie maintain a measurable gradient between 
myocardium and blood making the scan themselves challenging. 
 
1.2.5 T1 mapping and CRT 
 
Unlike LGE, T1 mapping has not been shown to be predictive of CRT response in a 
mixed cohort of ischaemic and non-ischaemic patients although there are only limited 
data examining this question.76   The relationship between CMR imaging and 
advanced electrocardiography measures such as fragmented QRS and 
vectorcardiography has not been the subject of previous enquiry. 
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1.3 Vectorcardiography  
 
Modern vectorcardiography (VCG) was developed in the 1950s by Dr E Frank.83 The 
VCG was designed to provide 3 dimensional electrocardiographic information using 3 
orthogonal planes (X, right to left axis; Y, head to feet axis; Z, antero-posterior axis).  
The VCG is acquired using 7 “Frank leads” (see Figure 11).   
 
Figure 11- Figure from Frank's original paper showing electrode position and the 3 





Performing a VCG using these leads is impractical as systems require electrodes to be 
placed on the back and as such the VCG has never entered mainstream clinical use.  
However, whereas the ECG only provides voltage data requiring intellectual 
supposition of vector direction, the VCG provides a visual depiction of the direction 
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of the dominant vector throughout the cardiac cycle.  The VCG also provides data of 
both QRS area and duration and T wave area and duration. Using a mathematical 
transformation, the VCG can now be accurately synthesised using standard 12 lead 
ECG data.84   
Nonetheless whilst the 12 lead ECG remains an integral to patient selection for CRT, 
a potential role for the VCG is only now beginning to be explored. 
 
With regard to CRT, it has been suggested that both QRS area and T wave area might 
provide additive information that can be used to identify patients most likely to 
benefit from CRT implantation.85 However, the relationship between structural 
changes in the ventricle and changes in VCG are unclear as is their relative 
contribution to identifying patients who may benefit from CRT implantation.  It is 
suggested that the interaction between VCG and CMR is a relevant area of enquiry 
given that they both may help to improve patient selection for CRT. 
 
 
1.4 Heart failure and implantable cardioverter defibrillators 
1.4.1 The evidence base for ICDs 
 
ICDs were first conceived in the 1980s but over the last 40 years the evidence base to 
support their use to protect against VA and sudden death has expanded significantly.  
Initial randomised studies investigated patients who had a secondary prevention 
indication (ie survivors of cardiac arrest or those with documented VA and found a 
survival benefit or reduction in sudden death in patients implanted with an ICD when 
compared with those randomised to taking amiodarone.  This benefit was significant 
in in the Anti-arrhythmic versus Implantable Defibrillators Study (AVID) but did not 
reach significance in the Canadian Implantable Defibrillators Study (CIDS). 86,87 
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Attention then turned to identifying patients who had not had an arrhythmic event but 
who might be at high risk of such events.  Post myocardial infarction patients with an 
EF< 35% have been shown to benefit from prophylactic ICD implantation.88  These 
finding were extended in SCD-HeFT trial which include patients with both an 
ischemic and non-ischemic cardiomyopathy.89 However, the role of primary 
prevention ICDs in non-ischemic patients is not entirely clear.  The DEFINITE study 
in 2004 found that ICDs reduced the risk of sudden death in NCM patients but not the 
risk of death by any cause.90 Furthermore the mean follow up time of DEFINITE was 
29 months.  The recent DANISH study has found that ICDs provide no survival 
benefit in the NCM population at 7 years although there was a reduction in 
arrhythmic death and some benefit noted in younger patients.91 
 
Interpretation of the findings of these studies is controversial.  What is apparent is that 
our ability to select appropriate patients for primary prevention ICDs is still poor.  
The highest event rate (appropriate shock) was 16.4% in MADIT 2, compared with 
5.4% in SCD HEFT and 4.4% in DANISH suggesting that large numbers of patients 
are being implanted with defibrillators “unnecessarily” and that the vast majority will 
never go on to receive an appropriate therapy.  This would suggest that there is a need 
for improved risk stratification which goes beyond ejection fraction and the clinicians 










As noted above, CMR can potentially identify both myocardial scar (LGE) as well as 
diffuse myocardial fibrosis (T1 mapping). The majority of studies assessing the  
predictive power of these CMR protocols have been small.93,94  However, a recent 
meta-analysis of >1100 patients with both NCM and ICM patients showed that the 




Myocardial scar is not homogenous.  At time of infarction, whilst there is cell 
necrosis resulting eventually in scar formation, other areas of myocardium often on 
the penumbra of infarcted areas form an admixture of viable and nonviable 
myocardium.96 These areas can form bridging channels around and through scarred 
tissue that can form substrate for re-entrant arrhythmia and exhibit altered pro-
arrhythmic automaticity.97 
 
Similarly, post-infarction scars on CMR vary in signal intensity (SI) and can be 
divided into the scar core (High SI) and the peri-infarct region or grayzone (Abnormal 
SI but not as high). Different definitions have been used to define this area of 
moderate SI (see Methods section).  The size of the grayzone has been shown to be a 
powerful predictor of mortality and predictor of both spontaneous VA and VA on 





T1 mapping has been shown to predict VA in a mixed cohort of NCM and ICM 
patients and has been shown to prognosticate in a perceived low risk cohort of 
patients with NCM.101,102 Furthermore, it is biologically attractive that such a measure 
of diffuse fibrosis should predict VA in NCM patients.103 It is unclear however, in a 
perceived high risk group of NCM patients with ICDs whether T1 mapping can 
specifically predict VA and appropriate therapy. 
 
 
1.4.3 Fragmented QRS to predict ventricular arrhythmia 
 
One of the potential clinical biomarkers that might be used to improve patient 
selection for both CRT and ICDs is the presence of fragmentation on the 12 lead 
ECG.  Breadth of QRS is already a key determinant of suitability for CRT and for 
primary prevention ICD implantation but work over the last 10 years has sought to  
use the ECG in a  much more sophisticated manner by looking for QRS 
fragmentation. 88,104.    
 
The concept of fragmented intracardiac electrograms and the signal averaged ECG as 
potential markers of arrhythmic risk significantly predates the assessment of 
fragmentation on the 12 lead ECG.105 It wasn’t until 2008 that, Pietrasik et al first 
published data in a large number of patients supporting the use of fragmented QRS on 
the 12 lead electrogram as a mechanism to risk-stratify patients with cardiovascular 
disease.106 Pietrasik found that fQRS predicted the risk of recurrent events in a post-
MI population who has transiently had q waves post infarction. This work was rapidly 
followed up by studies from Das et al. who published several studies demonstrating 
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the independent prognostic risk of fQRS in patients with coronary artery disease. 
107,108 This concept of risk was further refined to include the risk of ventricular 
arrhythmia in a mixed cohort of ischaemic and non-ischaemic cardiomyopathy.109In 
this study fQRS was found to be a stronger predictor of ventricular arrhythmia than 
wide QRS (defined as QRS>120ms).  Subsequent studies on similar cohorts have had 
mixed results with some confirming fQRS as an independent predictor of sudden 
death and others failing to find such an association110-112.  
 
A recent large meta-analysis of >5000 patients which included the above described 
studies found that fQRS is associated with increased relative risk of all-cause 
mortality in ICM and NCM patients (RR 1.71 (CI 1.02-2.85)) - and of sudden cardiac 
death (RR 2.20 (CI 1.05-4.62)).113 Subgroup analysis confirmed this risk separately in 
both aetiologies (NCM and ICM).  Interestingly there was no increased risk in 
mortality in patients with ICDs and the authors propose that this may be the result of 
ICD therapies preventing this outcome. Furthermore, fQRS had no independent 
predictive value in patients with an ejection fraction <35% suggesting that fQRS 
failed to add any discriminatory value to patients who are already high risk for both 
VA and death.  Importantly this cohort makes up the majority of those who qualify 
for a primary prevention device.   
 
Thus, these findings are potentially important in assessing fQRS in a cohort of ICD 
patients with low ejection fraction as the fQRS may fail to add any further predictive 





FQRS and scar 
 
Nonetheless it remains unclear quite what fragmentation on the QRS represents.  
Again the literature is not entirely consistent. Das et al demonstrated that fQRS has 
greater sensitivity than Q waves in detecting myocardial scar (85.6% vs 36.3%).108 
This large increase in sensitivity was offset by a slightly reduced specificity (99.2% 
vs 89%).  Conversely, Wang et al found that fQRS had an exceptionally poor 
sensitivity in detecting myocardial scar when compared with q waves (1.7% vs 
31.7%) and had a higher false positive rate in patients with normal perfusion scans 
(15.8% vs 1.4%).   
 
The above studies have used nuclear scanning to determine scar but CMR is better 
able to characterise scar and perfusion abnormalities than nuclear imaging and as such 
would be a preferable modality with which to understand fQRS fully.114  
 
A study of 86 patients found no relationship between LGE scar and fQRS in patients 
with NCM.  Indeed, the presence of scar was not significantly different (50.9% in 
patients with fQRS vs 45.5% in patients without fQRS; p=0.62)115  The same authors 
also found in a cohort of 186 patients who had a history of myocardial infarction that 
fQRS had poor accuracy compared with q waves for the detection of LGE on 
CMR.116 In the study LGE was only qualitatively identified as present or absent and, 
if present, subendocardial or transmural.  No study has sought to determine whether 
the volume of scar may be a factor in the presence or absence of fQRS.   It may be 
that fQRS represents myocardial fibrosis or the peri-infarct region rather than scar but 




1.5 Cost effectiveness in the National Health Service- rationing 
healthcare provision 
 
The National Health Service (NHS) provides the overwhelming majority of 
healthcare to the population of the United Kingdom. 98% of the funding it receives is 
from taxation and National Insurance contributions.  The cost of the service is 
enormous and spiralling with an increasingly elderly population with more complex 
medical problems. In 2015-2016, health spending made up 29.7% of the public 
spending budget with the NHS annual budget calculated at £116.4 
billion.(www.nhs.uk)  The Department of Health is seeking to make £22 billion of 
efficiencies by 2020-2021.117 
 
Meanwhile, the National Institute for Health and Care Excellence (NICE) continues 
to produce clinical guidelines incorporating clinical evidence and cost effectiveness to 
ensure patients are prescribed the most effective treatments to maximise potential 
outcomes given the inevitable financial restrictions that exist nowadays. Similar 
models of assessing treatments are beginning to be explored by other healthcare 
systems. Most notably, the American College of Cardiology and American Heart 
Association have stated that cost effectiveness should be referred to when new 
guidelines are drafted.118 
 
Chapter 7 of the NICE guidelines manual, 2012 relates specifically to how cost- 
effective measures should be assessed.  A gold standard methodology is described as 
the process by which decisions should be made as to which questions should be 
addressed.  The guideline manual then states 
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“It is acknowledged that “NICE” has limited resources and time to construct new 
economic analyses. Therefore, the complexity and number of new analyses will vary 
depending on what are considered priority areas and what information is required for 
robust decision making.” 
 
With this in mind, it is necessary for health researchers to research the cost –
effectiveness of their treatments wherever possible to try to maximise overall NHS 
budgets.  This should be done using the methodology that NICE prescribes wherever 
possible and using appropriate quality adjusted life year and incremental cost 






Chapter 2 METHODS 
2.1 SIMULTANEOUS INVASIVE ASSESSMENT OF CORONARY FLOW AND 
PRESSURE AND LV PRESSURE 
 
The experiments detailed in Chapter 3 required the invasive measurement of several 
haemodynamic indices simultaneously.  It was necessary to adapt tools generally 
available for clinical practice to enable these measures to be taken.  
 
2.1.1 Ascending aorta/ aortic root pressure 
 
As in clinical practice, aortic pressure was measured using a fluid-filled hollow multi-
purpose catheter with pressure being transduced externally via the catheter.  The 
pressure transducer was fixed to the catheter laboratory table to avoid error related to 
changes in position and initially zeroed at the level of the right atrium whilst the patient 
was lying on the catheter laboratory table.  This allowed beat to beat measurement of 
aortic blood pressure 
 
2.1.2 Coronary artery flow and pressure 
 
Coronary artery flow and pressure from both the LAD and Left Circumflex artery 
measured using the 9500 Combowire (Volcano corporation, US).  This is a 0.036mm 
diameter, 185cm guidewire which measures both flow velocity and pressure 











Coronary Flow Velocity measurement using the Combiwire 
 
The coronary flow velocity is measured by pulsed ultrasound.  A piezo-electric crystal 
on the tip of the wire acts as both transmitter and receiver of the ultrasound.  A 
proportion of the pulsed ultrasound waves emitted from the crystal are reflected back by 
blood cells within the sample volume in the vessel to the crystal.  The pulsed ultrasound 
allows the crystal to act as receiver in between ultrasound pulses.  The returning waves 
have a lower frequency than the emitted wavefront as the blood cells are moving away 
from the crystal.  This creates a Doppler shift which is proportional to the blood 
velocity.  Changes in this shift can be transformed into velocity (cm/s) assuming a 
constant speed of sound in blood and consistent frequency in transmission of the 
ultrasound signal.  The instantaneous peak velocity is the maximum velocity sampled 
and the average of these peaks can be used to obtain the Average Peak Velocity (APV) 




Ultrasound measurement requires the ultrasound beam to be parallel to the direction of 
flow to minimise underestimation of flow and thus in all experiments great care was 
taken to align the Combowire appropriately within the lumen of the vessel to optimise 
the Doppler signal. 
 
Coronary Pressure measurement using the Combowire 
 
The Combowire has a pressure sensor that uses the MEMS (Micro Electric Mechanical 
Systems) technology.  The sensor has a thin silicon diaphragm over a reference pressure 
chamber in which tiny resistors are embedded.  As pressure changes, flexing the 
diaphragm, so the resistance in the resistors alters.  These changes in resistance can be 
converted in real time into a pressure reading. 
 
“Simultaneous” measurement of pressure and flow 
 
Theoretically, wave intensity analysis requires both pressure and flow to be acquired at 
the exact same point but the sensors are in fact 5mm apart which is the minimum 
electronically feasible distance that has currently been achieved.  Davies et al. have 
shown that given the sampling frequencies used for both Doppler and pressure readings 
that any time delay is negligible (0.25-1ms) and thus this was not corrected for in the 
studies presented here.  Furthermore the magnitude of delay is variable on wave speed 






2.1.3 Left ventricular pressure 
 
Left ventricular pressure was measured using a Primewire (Volcano, Inc).  This wire 
also uses MEMS technology and was placed in the LV cavity.  The first derivative of 
pressure was used to assess LV contractility and lusitropy. 
 
2.1.4 ComboMap system 
 
The ComboMap console (see  
Figure 13) receives inputs from the pressure transducer (aortic pressure),  the 
Combowire (coronary flow and pressure) and the Prime wire (LV pressure) and 
displays data live (see Figure 14).  It allows live assessment of data quality.  Data can 
then be stored on a CD drive and analysed later. 
 










     
Figure 14- ComboMap console data screen (ECG, Pressure signals in red and yellow, 








The pressure signals for the Combowire, Prime wire and fluid filled catheter were 
compared at catheter laboratory table height and zeroed.  The Doppler signal was 
optimised for each patient in each vessel.  Both the wall filter and the instantaneous 
peak velocity (blue line in Figure 14) were adjusted to optimise the signal. 
 
2.1.5 Post processing of data 
 
Data was subsequently exported for analysis from the ComboMap and initially analysed 
using custom made software (Studymanager, AMC, Amsterdam).  This programme 
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allowed visualisation of data so that noisy or incomplete data could be omitted from 
analysis.  
 
For example, the programme automatically determines and annotates the R wave from 
which subsequent calculations are made.  Our investigations resulted in changing QRS 
morphology and importantly changing amplitude in a pre QRS pacing spike.  The 
programme allowed us to correct for failings in the automatic analysis.  The raw data 
was not altered or alterable using the programme. 
 
Following optimisation of the data, this could then be extracted and imported to a 
second custom made piece of software (Cardiac Waves, KCL, London). This software 
enabled wave intensity analysis to be applied to the coronary data and also provided the 





2.2 ACHIEVING ENDOCARDIAL PACING AND SYNCHRONIZING 
VENTRICULAR ACTIVATION WITH PRE-EXISTING DEVICE 
 
The invasive studies used a population of patients with a CRT already in situ.  To 
investigate the haemodynamic effects of endocardial LV pacing it was necessary to 
insert a roving mapping catheter (Biosense Webster) via the right femoral artery and a 
temporary pacing wire in the right atrium via the right femoral vein.  Atrial capture was 
confirmed with standard threshold testing.  The CRT devices and the mapping catheter 
were then programmed to sense the atrial pacing spike at a set atrioventricular delay.  
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Endocardial ventricular capture was confirmed by looking for changes in QRS 
morphology.  If there was any doubt then the pacing output on the CRT device was 
dropped to below thresholds to ensure ventricular capture. 
 
2.3 CARDIAC MAGENTIC RESONANCE IMAGING PROTOCOLS: LATE 
GADOLINIUM ENHANCEMENT, GRAYZONE AND T1 MAPPING 
2.3.1 CMR Protocol 
 
CMR imaging was performed as per King’s College London/ Guy’s and St Thomas’ 
Foundation Trust, standard clinical protocols.  All scans were acquired on a 1.5 Tesla 
MRI scanner with a 32 channel coil (Philips Healthcare, Netherlands).  An initial survey 
scan was performed to ensure registration and thoracic localisation. A stack of 12 to 14 
short– axis balanced steady state free precession slices covering the LV were acquired 
initially which allowed measurement of mass, volume and ejection fraction.  Gadobutrol 
contrast (0.2mmol/kg) was then injected intravenously and 10-15 minutes post 
injection, a Look-Locker sequence was acquired to determine the optimum TI 
contrasting the myocardium to blood pool. Subsequently, a further stack of short axis 
slices of the LV was acquired using an inversion-recovery gradient echo sequence with 
a repetition time/echo time of 3.4 and 2.0ms respectively, a flip angle of 25 degrees and 
a voxel size of 1.8x1.8x8mm. Images were triggered via the ECG for collection at end-
diastole.  These images were used for assessment of scar and grayzone. 
 
T1 mapping images were obtained pre and post the administration of gadolinium 
contrast. A single mid ventricular slice was acquired using a modified Look- Locker 
sequence with 11 phases over 3 cardiac cycles (3+3+5, repetition time/ echo time = 
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3.3/1.5ms, flip angle = 50 degrees, voxel size 1.8x1.8x 8mm with heart rate adapted 
triggered delay and a adiabatic prepulse to ensure complete inversion. 
 
A region of interest was then sampled post data acquisition remote from LGE 
enhancement in the septum to obtain T1native and T1post results. 
 
2.3.2 CMR Image analysis 
 
All images were analysed using CVI 42 (Circle Cardiovascular Imaging Inc., Canada).  
Volume, mass and function were measured and derived by visual assessment of the 
endocardial and epicardial borders in end diastole and end systole with subsequent 
automated calculation using the software. 
 
The quantitative assessment of scar with LGE was performed using the “X” standard 
deviation method and the full width half maximum method. The “X” standard deviation 
method defines scar as the region with signal intensity “X many” standard deviations 
above a remote reference region of interest in the myocardium deemed to be normal.  
The full width half maximum calculation defines scar as the region within the 
myocardium that has a signal intensity of at least 50% of the maximum signal intensity 
measured.   
 
The quantitative assessment of grayzone was also calculated using two methods. The 
first assessment subtracted the area of LGE identified using scar at 3 standard deviations 
from that at 2 standard deviations to describe the peri-infarct region.  The second 
calculated the percentage of myocardium between scar using full width half maximum 




All scar and grayzone measures were then expressed as a percentage of LV mass to 
normalise for ventricular size across patients. 
 
2.3.3 T1 mapping quantification 
 
The T1 maps were analysed using customised software with motion correction. (Osirix, 
Pixmeo, Geneva and Insight Toolkit).  As previously described, we performed linear 
regression analysis of the measured native T1 values on heart rate and then applied heart 
rate correction using a function of the mean heart rate of the study population to the 
native T1 values. 81,101 
 
2.4 ASSESSING FRAGMENTATION ON THE 12 LEAD ECG 
 
The method by which the presence of fragmentation on the 12 lead ECG is determined 
varies depending upon QRS duration.  This is due to the presence of notching in both 
LBBB and RBBB which would always fulfil the criteria set out for fragmentation in 
narrow QRS ECGs (<120ms). For my study I used the well-validated criteria used by 
Das et al for both narrow and wide qrs.108,119 
Narrow QRS (<120ms) 
One of three criteria are required to confirm QRS fragmentation in patients with a 
narrow QRS. These are 
1) an additional R’ wave making an RSR’ pattern  
2) notching in the nadir of the S wave 
3) >1R’ (fragmentation) 
in 2 contiguous leads 
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Several different morphologies of QRS fulfil these criteria which appear in Figure 15 
taken from Das et al.108 
 
Figure 15- Morphologies of fQRS in narrow QRS 
 
 
Wide QRS (>120ms) 
 
Fragmented LBBB/RBBB  
RBBB and LBBB were defined by the standard ECG criteria (QRS duration ≥ ︎ 120 
fragmented BBB was defined as various RSR ︎  patterns with or without a Q wave, 
with ︎ >2 R waves (R’) or >2 notches in the R wave, or >2 notches in the downstroke 
upstroke of the S wave, in 2 contiguous leads corresponding to a major coronary 












Fragmented paced QRS  
Paced QRS (pQRS) was defined as a wide QRS complex (duration >120 ms and 
without any evidence of QRS fusion) initiated by a paced spike in patients with a 
pacemaker or ICD. Fragmented paced QRS was defined by the presence of >2 R’ or >2 
notches in the S waves in 2 contiguous leads.  
Figure 16- Two ECGs demonstrating fragmented wide QRS taken from Das et al.119 
 
 
















Ensuring assessor competence in the assessment of fragmentation and settling 
disagreement 
For the study in which I looked at fragmentation, I enlisted the help of two colleagues, 
both cardiologists to review the ECGs.  They were both blinded to the CMR and 
outcome data. I created a training set of 20 ECGs which they reviewed and then we 
discussed difficult cases as a group.  For the study ECGs. Both colleagues analysed the 
ECGs separately and I reviewed the results.  There was 94% concordance between the 
two cardiologists and the remaining ECGs were adjudicated unanimously. 
 
2.5 VECTORCARDIOGRAPHY  
Standard digitised 12 lead ECGs were acquired prior to CRT implantation. (MAC 
5500HD, GE Healthcare, Chicago, US).  The digital PDF files with vector graphics 
were used to extract the original digital ECG-signal. VCGs were semi-automatically 
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synthesized from these digital ECG signals using a custom-made software 
programmed in MATLAB 2016 (Mathworks, Natick, NA).85 The Kors transformation 
matrix was used to transform the 12-lead ECG to reconstructed VCGs.120 The onset 
and end of the QRS-complex and end of the T-wave were manually set on the three 
overlaid orthogonal leads (X, Y, and Z)of the VCG. QRS duration (QRSd) was 
defined as the onset to end of the QRS complex on the VCG orthogonal leads (see  
Figure 18).  QRSarea, Tarea and QRSTarea were defined as the 3D areas of respectively 
the QRS complex, T wave and QRST loop from the VCG between the loop and 
baseline in X, Y, and Z direction calculated as QRSarea = (QRS2area,x + QRS2area,X  + 
QRS2area,X)1/2,  Tarea  = (Tarea2,x + Tarea2,X  + Tarea2,X)1/2 and QRSTarea = (QRSTarea2,x + 
QRSTarea2,X  + QRSTarea2,X)1/2.85  
 







2.6 ASSESSING CRT RESPONSE BY ECHOCARDIOGRAPHY 
 
Left ventricular reverse remodelling was defined as a reduction in the LV ESV of  
>15% at 6 months post CRT implant as measured on transthoracic echocardiography 






Chapter 3 INVESTIGATIONS INTO THE HAEMODYNAMIC 
EFFECTS OF CARDIAC RESYNCHRONISATION THERAPY    





The increase in global coronary flow seen with conventional biventricular pacing is 
mediated by an increase in the dominant backward expansion wave (BEW).  Little is 
known about the determinants of flow in the left-sided epicardial coronary arteries 
beyond this or the effect of endocardial pacing stimulation on coronary physiology. 
Methods and Results: 
11 patients with a chronically implanted biventricular pacemaker underwent an acute 
haemodynamic and electrophysiological study.  5/11 patients also took part in a left 
ventricular endocardial pacing protocol at the same time.  Conventional biventricular 
pacing (BIVCS) resulted in a 9% increase in flow (average peak velocity) in the left 
LAD mediated by a 13% increase in the BEW(p=0.004).  Endocardial pacing (BIVEN) 
resulted in a 27% increase in flow mediated by a 112% increase in the forward 
compression wave (FCW) and 43% increase in the BEW (p=0.048 & 0.036 
respectively).  There were no significant changes in circumflex (Cx) parameters.  
BIVCS resulted in homogenization in timing of coronary flow compared with baseline 
(mean difference in time to peak in LAD vs. Cx of the FCW 39ms (baseline) vs 3ms 
(BIVCS)(p=0.008); BEW 47ms (baseline) vs 8ms (BIVCS)(p=0.004.)) 
Conclusions: 
Epicardial and endocardial pacing result in increased coronary flow in the LAD and 
homogenization of the timings of waves that determine flow in the LAD and Cx.  The 
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increase in both the FCW and BEW with endocardial pacing may be the result of a 
more physiological activation pattern than epicardial pacing which resulted only in an 
increase in the BEW.  
 
3.1.2 Background 
Cardiac resynchronisation therapy (CRT) is an effective treatment for patients with 
systolic heart failure and electrical dyssynchrony, resulting in improvements in both 
symptoms and mortality.10 Depending upon the endpoint assessed, between 30% and 
40% of patients fail to improve with CRT.24 Metrics created to improve patient 
selection and predict response have often appeared encouraging in small single centre 
studies but have lacked reproducibility when extrapolated to multi-centre trials.18 As a 
result, there has been increasing interest in both the pathophysiology of dyssynchronous 
heart failure in an attempt to understand the mechanical sequelae of electrical 
dyssynchrony and new methods of ventricular stimulation such as endocardial and 
multipoint pacing to improve CRT response. 28,32,121-123 One area of research is the 
effect of impaired electrical activation and CRT on coronary haemodynamics and 
physiology, as recent data from animal models have indicated the importance of blood 
flow in CRT response.35  
 
The coronary vasculature is unique in the human body in that the majority of flow 
occurs during diastole.  Using advanced invasive techniques, it has been possible to 
demonstrate that flow is mediated principally by the forward propulsion of blood 
through the coronary tree in systole (a dominant forward travelling compression wave 
(FCW)) and by a relatively larger backward travelling expansion (suction) wave (BEW) 
generated by relaxation of the ventricle in diastole.62 There is now evidence that the 
amplitude and wavelength of these waves are effected by CRT when measured in the 
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left main coronary artery (LMCA).71 However, relative workload and myocardial stress 
is not homogenous in the dyssynchronous left ventricle. Ventricular activation with left 
bundle branch block (LBBB) results initially in septal contraction with delayed 
activation and contraction of the lateral wall.   This early contraction occurs prior to 
development of tension in the lateral wall resulting in reduced septal work compared 
with normal contraction.  Conversely the lateral wall contracts against a pressure-loaded 
ventricle causing an increase in lateral wall work compared with synchronous 
activation. 37,124 
 
Conventional biventricular pacing delivered epicardially from the coronary sinus 
(BIVCS) can increase left anterior descending (LAD) coronary flow and acute changes 
in LAD flow may predict response to CRT but little is known about the effects of 
BIVCS on the wave energy that determines coronary flow in the left-sided coronary 
system. 55,125Similarly, whilst there is increasing data about the beneficial acute effects 
of LV endocardial pacing (BIVEN) on cardiac work and acute contractility, there are no 
data describing the effects of LV endocardial pacing on coronary blood flow. 32,126Given 
the heterogeneity of regional work in the dyssynchronous ventricle a more detailed 
examination of the individual epicardial arteries may give insights into the regional 
effects of myocardial contraction on the different constituents of coronary blood flow 
during both epicardial and endocardial LV pacing. 
 
We sought to describe the effects of both standard CRT via LV epicardial pacing from 
the coronary sinus and BIVEN on coronary flow. By applying wave intensity analysis 
to simultaneously obtained coronary pressure-Doppler flow data we sought to describe 
the effect of pacing from different sites (epicardial and endocardial) on coronary 





The study received approval from the Local Research Ethics Committee and was 
conducted in accordance with the Declaration of Helsinki. All participants provided 
written and informed consent.  We obtained simultaneous electrophysiological and 
haemodynamic measurements in 11 patients with a previously implanted standard CRT 
device with an epicardial LV lead in the lateral/postero-lateral wall.  Arterial access was 
gained in both the femoral and radial arteries.  A 0.014′′ Doppler wire (ComboWire
TM 
model 9500, Volcano Corporation) was advanced to the proximal LAD and was 
advanced to a central location within the proximal LAD where a high signal-to-noise 
ratio was obtained.  A Primewire (Volcano Corporation) was placed in the LV cavity to 
allow measurement of acute contractility by dp/dt max.33 
To study the effects of LV endocardial pacing on coronary flow, 5 of the 11 patients 
agreed to undergo a more comprehensive study in which a roving endocardial pacing 
catheter was placed in the LV to perform LV endocardial pacing.  Several endocardial 
positions (mean 4 (2 for each artery)) were tested in the 5 patients and the site with the 
highest APV in each artery selected for analysis. Patients underwent an acute pacing 
protocol with assessment of different pacing configurations.  The study was then 
repeated with the Combowire moved from the LAD to the circumflex artery (Cx).  In 5 
cases the Cx was assessed before the LAD.  Intracoronary adenosine was given as a 
bolus dose of 36mcgs to induce hyperaemia to further investigate the effect of pacing 
from different sites on coronary haemodynamics.  
Baseline measurements were taken for patients in sinus rhythm in AAI mode.  For 
patients in atrial fibrillation or with complete heart block, the baseline comparator 
rhythm was right ventricular pacing with atrial synchronous pacing in the latter group.  
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When comparisons were made between baseline and right ventricular pacing those 
whose baseline required RV pacing were omitted from analysis.  All studies were 
performed with pacing 10 beats above the intrinsic rate or at 70 bpm in the case of 
patients with underlying AV block to control for the Bowditch effect.127 Atrio-
ventricular (AV) and ventriculo-ventricular (VV) delays were set as per previous 
standard clinical echo optimisation using the doppler mitral inflow and left ventricular 
outflow tract velocity time integral metrics respectively.  Baseline measures were 
reassessed between different pacing configurations to control for possible drift.   
 
Patients received dual antiplatelet therapy prior to the procedure in case of the need for 
emergency percutaneous intervention and received boluses of heparin to keep an 
activated clotting time (ACT)>300s. 
 
The first three to five beats recorded after a change in pacing protocol were selected for 
analysis according to the following criteria which are similar to those employed by 
other groups:71  
1) Elapse of an initial 10 seconds to stabilise the new pacing parameter  
2) Exclusion of the beat preceding an ectopic and the three beats following an 
ectopic 
3) When a physician who was blinded to the study hypotheses deemed the signals 
to be of sufficient quality for analysis 
Data analysis involved a two stage process.  The raw data was analysed using the 
Studymanager programme (Volcanocorps, Philips, Netherlands).  Wave intensity 
analysis was then applied to the coronary data using a custom-made programme, 
Cardiac Waves (KCL, London). Data were sampled at 250 Hz.  Details of the 
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methodology used to perform wave intensity analysis for data analysis have been 
previously described. Briefly, a Savitzky–Golay convolution method was adopted, 
using a polynomial filter to refine the derivates of the aortic pressure and velocity 
signals.58,128 The selected three to five consecutive cardiac cycles were gated to the ECG 
R wave peak, with ensemble averaging of aortic pressure, Pd, APV, and heart rate.  Net 
coronary wave intensity (dI) was calculated from the time derivatives (dt) of ensemble-
averaged coronary pressure and flow velocity (U) as follows: dI=dPd/dt×dU/dt. 
58,62 
Coincident (microcirculation- derived) backward and (aorta-derived) forward 
propagating waves were separated assuming blood density to be 1050 kg/m3 and 
estimating coronary wave speed using the sum of squares method. 58,61The area beneath 
the 2 most prominent wave energies identified were analyzed and included in this 
article. These were the positive, forward-directed (aorta-derived) compression wave 
(FCW), occurring at the onset of systole and the backward expansion waves (BEW), the 
first negative wave occurring at the onset of ventricular relaxation, identified by the 
onset of diastole.  An example of the data following analysis is demonstrated in graphic 
form in Figure 19. 
  




Acute contractility data measured by dP/dt (black dashed line) and the constituent 
waveforms (forward‐travelling waves are shown in dark green, and backward‐
travelling waves are shown in blue). The large shaded green area is the forward 
compression wave; the larger blue area is the backward expansion wave. dP/dt, rate of 
rise of LV pressure; WI, wave intensity. 
 
3.1.4 Statistical Analysis 
Statistical analysis was performed using IBM SPSS version 22.0.  Rather than assume 
normality, coronary flow data was analysed as a non-parametric variable using the 
Friedman’s test (the non-parametric equivalent of the ANOVA test for repeated 
measures.)71 Where the Friedman test was significant comparisons between pairs of 
states were made by using the Wilcoxon signed rank test, with probability values 
calculated comparison-wise.  For normally distributed data, paired two-sided student t- 
tests were used to compare means. Demographic data is presented as means with 
standard deviations.  Data regarding the AV and VV delays is presented as medians and 




12 patients consented to take part in the study.  In 1 patient it was not possible to 
complete the protocol due to problems in getting a stable signal from the Combowire 
and this patient was excluded from further analysis. Patient demographics for the 
remaining 11 patients are shown in Table 3. There were no complications as a result of 
the acute procedure. The median AV delay was 125ms (range 100-140ms) and the 
median VV delay was LV ahead by 30ms (range 0ms - LV ahead by 40ms). 
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Table 3- Demographic data of patients 
 Mean (S.D) 
Age (years) 59.9 (9.38 ) 
Gender 9 male, 2 female 
Aetiology 
(ICM- defined as previous infarct of flow 
limiting coronary disease at angiography) 
8 NCM/ 3 ICM 
QRS morphology 8 LBBB 
2 NSIVCD 
1 RBBB 
QRS duration (ms) 156.6 (20.1) 
EF pre implant (%) 24 (10.5) 
Sinus Rhythm 8/11 
Time since implant (days) 1027 (967) 
ACE inhibitors 11/11 
Betablockers 11/11 
Aldosterone Antagonists 9/11 
 
3.1.5.1 Effect on coronary flow with different pacing states 
There was no change in LAD flow when intrinsic conduction was compared with RV 
pacing (-4.5%, p=0.123). Conventional biventricular pacing (BIVCS) from the 
chronically implanted epicardial LV lead increased LAD flow significantly from 
baseline (+8.7%; p=0.033) and was further increased with the optimal endocardial 




Figure 20). BIVEN pacing resulted in an increase in LAD flow from BIVCS but this 
was not significant (+6.6%; (mean increase from baseline in 5 pts BIVCS +20.2% vs 
BIVEN +27.0%; p=0.748). APV from the Cx showed no significant variation 




Figure 20- Percentage changes from baseline of coronary flow (APV) in the LAD and 
the Cx with different forms of pacing. 
 
 
APV, average peak velocity; BIVCS, conventional biventricular pacing; BIVEN, 
biventricular endocardial pacing; Cx, circumflex artery; LAD, left anterior descending 
artery; RV, right ventricle. 
Analysis of the 8 patients with LBBB demonstrated a significant increase in LAD flow 
with BIVCS from baseline (+10.2%, p=0.034) with no significant change in Cx flow 
(p=0.917). Analysis of the 8 patients in sinus rhythm demonstrated a significant 
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increase in LAD flow with BIVCS from baseline (+10.1%, p=0.005) with no significant 
change in Cx flow (p=0.6) 
 
3.1.5.2 Effect of pacing on wave intensity analysis energy profile 
 
There was a significant increase in the magnitude of the BEW in the LAD with BIVCS 
when compared with baseline (mean area 6422.8 W/m2/s at baseline increased to 
7281.9 W/m2/s with BIVCS; (13% mean increase) p=0.004).  BIVEN facilitated a 
significant increase in the area above the wave to a mean of 8200.3 W/m2/s vs 5744.1 
W/m2/s; p=0.036.  The difference between BIVEN LAD BEW and BIVCS LAD BEW 




























Figure 21- Percentage change from baseline of the area above the BEW and below the 






Percentage change from baseline of the area above the BEW and below the FCW in the 
LAD with different pacing regimens. BEW indicates backward expansion wave; BIVCS, 
conventional biventricular pacing; BIVEN, biventricular endocardial pacing; FCW, 
forward compression wave; LAD, left anterior descending artery. 
 
There was no difference in the area under the FCW in the LAD with a mean increase 
from 2668.5W/m2/s at baseline to 3027.0 in BIVCS (p=NS).  However, the optimal 
BIVEN position also resulted in a significant increase in the energy of the FCW (mean 















Figure 21 and Figure 22). 
Figure 22- An example of wave intensity analysis in the left anterior descending 
artery of 1 patient: (A) baseline, (B) BIVCS, (C) BIVEN. Note the increase in the 







BEW indicates backward expansion wave; BIVCS, conventional biventricular pacing; 
BIVEN, biventricular endocardial pacing; WI, wave intensity. 
 
There was no difference in the magnitude of the BEW in the Cx with BIVCS when 
compared with baseline (mean 11047.2 W/m2/s at baseline reduced to 8666.6 
W/m2/s) (p=0.237). There was a non-significant reduction in the size of the BEW for 
the patients who underwent the endocardial procedure (mean area under the BEW at 
baseline 13704.6 8 W/m2/s  vs largest endocardial 5825.5 W/m2/s; p=0.053).  With 
regard to the area under dominant FCW, there was no change in the energy from 
baseline with BIVCS (baseline 4501.64 8 W/m2/s vs BIVCS 3229.2 W/m2/s; 
p=0.123) and best BIVEN (baseline 4548.4 8 W/m2/s vs endocardial 1910.3 W/m2/s 
p=0.176)(see Figure 23). 
 
Figure 23- Percentage change from baseline of area above the BEW and below the 





BEW indicates backward expansion wave; BIVCS, conventional biventricular pacing; 
BIVEN, biventricular endocardial pacing; Cx, circumflex artery; FCW, forward 
compression wave. 
 
3.1.5.3 Change in timings of coronary waves with application of biventricular 
pacing: coronary resynchronization 
 
The time to the peak of the dominant BEW was significantly delayed between the LAD 
and Cx at baseline in patients with a non-ischaemic aetiology (284ms in the LAD 
compared with 331ms in the Cx (p=0.01)(see Figure 24).  This was corrected by BIVCS 
(mean LAD 289ms vs  mean Cx 297ms (p=0.566)) The reduction of the difference 
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between the time to peak of the BEW in LAD vs Cx by BIVCS was significant (mean 
47ms at baseline vs 8ms;p=0.004)(see Figure 24).   
 
When assessing the FCW in a similar manner, the time to peak of the FCW at baseline 
was significantly different between the LAD and Cx (30ms vs 69ms; p=0.03) with a 
reduction in the difference of these timings with BIVCS (56ms (LAD) vs  53ms (Cx); 
p=0.715ms).  The reduction of the difference to peak of the FCW was also significant 


















Figure 24- Coronary resynchronization: Delay between the time from R wave to peak 







BEW indicates backward expansion wave; BIVCS, conventional biventricular pacing; 







3.1.5.4 Coronary Flow Velocity Reserve (CFVR) in the LAD and Cx 
 
Hyperaemia was induced at baseline and with BIVCS pacing. There was a significant 
difference between the baseline LAD CFVR  ((mean 2.35) and with BIVCS (mean 
2.05);p=0.02). Conversely, there was a non-significant increase in the CFVR in Cx 
artery from 2.1 to 2.46 with BIVCS pacing; (p=0.349)(see Figure 25). 
 
Figure 25- The effect of withdrawal of CRT on CFVR in chronically implanted CRT 
patients. BIVCS indicates conventional biventricular pacing 
 
 
CFVR, coronary flow velocity reserve; CRT, cardiac resynchronization therapy; Cx, 







To our knowledge, this study is the first to comprehensively analyse the effect of 
epicardial and endocardial pacing on the constituent waveforms of coronary flow in the 
LAD and Cx coronary arteries.  
 
The principal findings were as follows: 
 
(i) increased flow in the LAD with BIVCS and BIVEN was the result of increase in the 
BEW. 
(ii) In addition to an increase in the BEW, BIVEN pacing increased coronary flow with 
a significant increase in the FCW in the LAD. 
(iii) The time to the peak of the FCW and BEW is homogenized between the LAD and 
Cx following CRT.  
(iv) Cx flow and the constituent determinants of flow did not alter with BIVCS or 
BIVEN 
 
The effect of biventricular pacing on coronary flow and physiology has been an area of 
inquiry for many years with discussion as to whether changes noted are merely the 
result of restoration of synchronous mechanical activation or related to changes in 
underlying myocardial oxygen supply and demand.38,46 There has been a gradual 
refinement of our understanding of how coronary physiology is affected by the 
dyssynchronous ventricle in recent years.71,129 However, there remains significant 
disagreement within the literature as to the effect pacing has on coronary flow.33,71,130 
Our findings provide new insight on the effect of epicardial and LV endocardial pacing 




3.1.6.1 Coronary flow: comparison with previous studies 
 
The significant increase in flow in the LAD with BIVCS pacing accords with recent 
studies. 55,129However, the neutral effect on coronary flow in the Cx artery differs with 
Itoh et al who found that biventricular pacing increased both LAD and Cx flow but this 
was in the acute setting soon after device implant.   Our data may offer some 
explanation with regard to the differing results of studies looking at regional and global 
myocardial blood flow non-invasively:  these demonstrate either no change in regional 
myocardial blood flow or correction of a septal perfusion defect with CRT. 41,48,50,52Our 
findings of minimal changes in the Cx combined with an increase in the LAD with 
BIVCS and BIVEN may explain these apparent divergent findings.  If we accept that 
CRT increases global (LMCA) flow velocity, as per Kyriacou et al., our findings 
suggest that this increase in flow preferentially affects the LAD i.e there is an increase 
in flow to the LAD with unchanged Cx flow rather than a redistribution of an 
unchanged global blood flow towards the LAD. This may explain why imaging 
modalities do not report a redistribution in flow (as there is none) but why CRT has 
been noted to reverse septal perfusion abnormalities (through increase LAD flow 
secondary to increased global flow).  
   
Equally, the noted significant reduction in CFVR in the LAD with BIVCS and non-
significant increase in CFVR in the Cx contrasts with other studies showing increased 
CFVR in the LAD with CRT. 129,130Our findings may appear counterintuitive as one 
might expect more physiological electrical activation to have a positive effect on 
parameters such as CFVR.  However, our reported reduction in CFVR with BIVCS may 
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reflect the multi-faceted aetiology of the impaired septal flow at baseline and during 
hyperaemia in this cohort of patients with chronically implanted biventricular devices. 
 
CFVR levels in the LAD and Cx were below those seen in health suggesting a 
generalised blunted hyperaemic response reflecting microvascular dysfunction which 
cannot be overcome by CRT.  Components of microvascular dysfunction which CRT is 
likely unable to overcome include the anatomical disruption of the microvasculature by 
fibrosis and extracellular matrix, decreased myocardial capillary density and impaired 
capillary vasodilation. 131-134Indeed the only component of microvascular resistance that 
seems likely to be altered by CRT is the effect of compressive forces related to high end 
diastolic pressures.46  
 
It is important to interpret our findings within the context of our studied population i.e 
patients who had chronically received CRT and thus potentially undergone ventricular 
remodelling.  It is suggested that the sudden withdrawal of BIVCS pacing results in new 
onset mechanical dyssynchrony and thus acts as potential sudden mechanical 
obstruction to LAD flow with attendant increase in diastolic pressures.135 When BIVCS 
pacing is reintroduced this obstruction is relieved resulting in an increase in flow.  
Conversely this mechanical obstruction can be overcome during hyperaemia both at 
baseline and with BIVCS pacing as a result of the chronic remodelling process resulting 
in similar hyperaemic flows.  The net effect of this is a reduction in CFVR when BIVCS 
is compared with baseline. Conversely the flow in the Cx artery is relatively unaffected 
by the cessation of BIVCS pacing (with a trend to a reduction in flow).  In the presence 
of a fixed hyperaemic flow this will manifest as the non-significant trend towards an 




The potential explanation for the increase in LAD flow may be a result of increased 
contractility.  This would be biologically attractive and accord with Kyriacou’s work on 
the effect of CRT on myocardial oxygen demand.34 The increase in flow in the LAD 
from baseline to BIVCS could represent a physiological increase in blood flow to help 
meet the increased myocardial oxygen consumption required as a result of the increased 
contractility and septal work.  However, our findings do not preclude a second 
possibility that the increase in LAD APV when pacing BIVCS is the result of changes 
in microvascular resistance secondary to correction of mechanical dyssynchrony and the 
wave intensity data are consistent with the hypothesis that these local factors may play 
an important role. 
 
3.1.6.2 Wave intensity analysis of the left sided coronary circulation: 
 
The increase in LAD flow with BIVCS was significantly related to an increase in flow 
mediated by the BEW suggesting increased suction by improved regional relaxation of 
the microvasculature.  The increase in LAD flow during BIVEN was related to an 
increase in both the FCW and BEW.  Whilst the reason for the increase in BEW with 
BIVEN is likely similar to that proposed for BIVCS, it is suggested that the increase in 
the FCW in the LAD is likely related to both global effects of forward propulsion but 
also importantly changes in the septal microvasculature as there was no increase noted 
in the FCW in Cx.  This change in microvasculature might be the result of the more 
physiological activation pattern that LV endocardial pacing is thought to be able to 
achieve by early activation of the specialised Purkinje network.136  
 
With regard to the Cx artery, we found a non-significant trend to reduction in both the 
FCW and BEW.  With regard to the BEW this would conform with the hypothesis that 
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BIVCS pacing reduces work in the lateral wall and that therefore the local 
intramyocardial pressure generated to create the suction for the BEW is reduced.  This 
combined assessment of the changes in the FCW and BEW with different pacing 
regimens demonstrates that both regional and global mechanisms are involved in 
determining coronary flow to different parts of the myocardium.  This duality is further 
developed when considering the synchronisation of timings of the FCW and BEW in 
the LAD and Cx following CRT. 
 
3.1.6.3 “Coronary Resynchronisation” 
 
By measuring the time to the peak of the FCW and BEW in both the LAD and CX at 
baseline and with BIVCS pacing we are able to demonstrate for the first time in humans 
that there is a difference between the timings of flow in the LAD and Cx arteries in 
dyssynchronous heart failure.  Furthermore, we have shown that this is corrected 
significantly with regard to the time to peak of both the FCW and BEW.  The 
implications of this are twofold.  Firstly, such homogenisation is suggestive of 
generalised cardiac resynchronisation.  Secondly however, it has previously been 
recognised that the waves measured in coronary flow are, in patients with normal 
coronary arteries, generated by the global effects of cardiac contraction and relaxation 
causing propulsion of blood forward (FCW) and suction of blood backwards (BEW) 
respectively.  Changes in the size of waves have been correlated to wall thickness in 
concentric hypertrophy suggesting that waves are dependent on the myocardium and 





Our findings relating to dyssynchronous heart failure and the effect of BIVCS pacing 
are the first to demonstrate the effect of both regional and global forces on the coronary 
waves. It is proposed that the ability of CRT to homogenize these timings suggests that 
dyssynchrony causes regional changes in the microvascular energetics which are 
correctable with biventricular pacing.  With regard to the FCW the timings are 
homogenized to a timepoint between the time to peak of the LAD and the Cx at 
baseline.  This accords with the concept that the FCW is generated by the forward 
propulsion of blood down the coronary arteries as a result of LV systolic contraction.  
Conversely, the homogenization of the larger BEW is largely achieved by a reduction in 
the time to peak of the BEW in the Cx artery rather than significant change in the LAD 
timings.  This is biologically attractive as any negative pressure generated in the LV 
cavity in diastole relies on the microvasculature as a conduit to create the suction for the 
BEW.  Thus delayed lateral wall relaxation before resynchronisation of this conduit will 
result in a delayed time to peak in the BEW in the Cx artery and the reduction of the 
time to peak of the BEW that we observed following CRT. 
 
From the clinical perspective, our study offers potentially new explanations as to how 
conventional CRT may exert its benefit.  It is suggested that changes in coronary blood 
flow and wave energy need to be studied in prospective studies at the time of implant to 
determine if they may offer a role in patient selection.  As noted above, both electrical 
resynchronisation and correction of mechanical dyssynchrony have not been found to be 
accurate predictors of response to CRT.137   Whilst changes in coronary haemodynamics 
are also unlikely to be a single predictor of response, it may be that they have a role in a 
more integrated patient selection pathway in difficult cases or be used as a target for 
“optimisation” in non-responders using emerging non-invasive techniques.138 Further 




There is evidence that BIVEN has an acute effect on LV function beyond conventional 
CRT but further research is necessary to determine the mechanisms by which this 
occurs.  It is again suggested that this be performed at the time of device implant with 
attention paid to coronary wave energetics as a component in such studies. 32,139It is 
highly desirable that we have an understanding of the mechanistic effects of such 
systems before their use in the clinical environment becomes routine. 
 
3.1.6.4 Study Limitations 
 
The patients studied were not selected for any particular clinical characteristics and 
reflect a real world CRT population.  However our sample size is small and it is 
important that we remain guarded with regard to the generalizability of our results to the 
whole CRT population.  However, the number of patients studied is similar to other 
similar invasive studies.57 The invasive procedural burden for patients is very high and 
not suitable for routine clinical practice. However, emerging non-invasive techniques71 
to measure wave intensity are increasingly being described and these may allow larger 
studies to be performed.138 All patients studied were chronically implanted with CRT 
devices.  This makes extrapolation of our findings to pre-implant patients difficult; 
however many of the findings could, if anything, be amplified in the pre-implant 
population.   Nonetheless the prolonged time between implantation of the device and 
study participation means that any association between blood flow changes, wave 
energetics and “response” to CRT cannot be clearly made.  As noted above, further 
studies at the time of implant are required.  By fixing the heart rate we controlled for the 
effect that changes in chronotropy can cause to inotropy (the Bowditch effect).  






The data presented develop our understanding of coronary physiology in 
dyssynchronous heart failure with biventricular pacing beyond the left main coronary 
artery and give new insight into the effect of regional and global mechanics as well as 
coronary wave energies on coronary flow.  BIVCS and BIVEN increase the 
microcirculatory derived BEW in the LAD with no change in the Cx artery.  The time to 
peak of the BEW is homogenized in the LAD and Cx following CRT.  Together these 
findings suggest that the coronary BEW is susceptible to changes in local forces rather 
than being solely dependent on increased global LV systolic and diastolic function as 
had previously been reported.  The demonstrated increase in LAD coronary flow with 
an increase in the LAD FCW with endocardial rather than epicardial pacing offers 
offers an exciting mechanism to further increase coronary flow, which may be mediated 













3.2 CHANGES IN CONTRACTILITY DRIVE CHANGES IN CORONARY 






Biventricular pacing has been shown to increase both cardiac contractility and coronary 
flow acutely but the causal relationship is unclear.  We hypothesised that changes in 
coronary flow are secondary to changes in cardiac contractility.  We sought to examine 
this relationship by modulating coronary flow and cardiac contractility. 
 
Methods 
Contractility and lusitropy were altered by varying the location of pacing in 8 patients.  
Coronary autoregulation was transiently disabled with intracoronary adenosine. 
Simultaneous coronary flow velocity, coronary pressure and left ventricular pressure 
data were measured in the different pacing settings with and without hyperaemia and 
wave intensity analysis performed.  
 
Results 
Multisite pacing was effective at altering left ventricular contractility and lusitropy (pos. 
dp/dtmax -13% to +10% and neg. dp/dtmax -15% to +17% compared to baseline). 
Intracoronary adenosine decreased microvascular resistance (362.5 mmHg/s/m to 156.7 
mmHg/s/m,p<0.001) and increased LAD flow velocity  (22cm/s vs 45cm/s,p<0.001) but 
did not acutely change contractility or lusitropy. The magnitude of the dominant 
accelerating wave, the Backward Expansion Wave, was proportional to the degree of 
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contractility as well as lusitropy (r=0.47, p<0.01 and r=-0.50,p<0.01). Perfusion 
efficiency (the proportion of accelerating waves) increased at hyperaemia (76% rest vs 
81% hyperaemia, p=0.04). Perfusion efficiency correlated with contractility and 




Acutely increasing coronary flow with adenosine in patients with systolic heart failure 
does not increase contractility.  Changes in coronary flow with biventricular pacing are 
likely to be a consequence of enhanced cardiac contractility from resynchronization and 
not vice versa. 
 
3.2.2 Introduction 
Cross-talk between the coronary vasculature and cardiac muscle has been proposed as a 
theory to understand the simultaneous effects of coronary blood flow on cardiac 
contractility and vice versa.140  
Reduced coronary flow in the Left Anterior Descending (LAD) Artery and 
corresponding perfusion defects have been noted in patients with dyssynchronous left 
ventricular activation.41,52,53 Furthermore, Cardiac Resynchronization Therapy (CRT) 
has been shown to increase LAD flow and correct these perfusion defects.57 It is unclear 
whether the observed increases in LAD flow are a bystander effect of electrical 
resynchronization or whether the increase in coronary flow is mechanistically important 
in mediating some of the physiological effects of CRT, resulting in the recruitment of 




Coronary wave intensity can be calculated from simultaneously acquired coronary flow 
and pressure measurements. It provides temporal information on the nature and origin 
of forces that drive and impede myocardial perfusion.65 This makes it an ideal tool to 
investigate cardiac-coronary coupling, specifically the relationship between changes in 
LAD flow, acute left ventricular (LV) contractility and electrical activation.  Typically, 
as many as six waves have been described with the vast majority of flow being driven 
by a dominant backward travelling expansion wave (BEW) that ‘sucks’ blood through 
the coronary artery and a dominant forward compression wave (FCW) which derives 
from the ejection of blood from the left ventricle into the aorta and down the coronary 
arteries.62,64 The effect of changes in both contractility and microvascular resistance on 
coronary wave energy have previously been studied in a canine model and used to 
identify the causes of the systolic impediment to coronary flow velocity.141 Kyriacou et 
al. demonstrated in a group of patients with CRT that an acute increase in contractility 
was associated with an increase in the BEW in the left main coronary artery.71 This is 
the only clinical study to date where coronary wave energy and coronary flow have 
been correlated with changes in acute LV contractility. Contractility and microvascular 
resistance have not previously been simultaneously modulated in humans and hence 
their relative impact on wave energy remains unclear.  
 
We hypothesised that increased LAD coronary flow with hypaeremia would not effect 
LV contractility. We also sought to characterise the relationship between changes in 
acute LV contractility and lusitropy with the dominant wave energies driving coronary 





We investigated a group of patients with a CRT device as a clinical model that allowed 
manipulation of both coronary blood flow and contractility.  Patients who had been 
implanted with a CRT device and were known to have unobstructed coronary arteries at 
invasive angiography were invited to take part.   
 
Cardiac contractility and lusitropy were altered by pacing from different points in the 
left and right ventricles.  The first derivative of LV pressure was used to assess 
contractility and relaxation (pos. dp/dtmax and neg. dp/dtmax respectively).   
Microvascular resistance was altered by inducing hypaeremia with intracoronary 
adenosine.  
 
The study received approval from the Local Research Ethics and was conducted in 
accordance with the Declaration of Helsinki.  All patients gave written informed 
consent prior to taking part in the study. 
Patients received dual antiplatelet therapy prior to the procedure and received 
unfractionated heparin to keep an activated clotting time >250s. Arterial access was 
gained via femoral and radial arteries.  A 0.014′′ Doppler wire (ComboWire
TM 
model 
9500, Volcano Corporation) was advanced to the proximal LAD to make simultaneous 
measurements of intracoronary pressure and Doppler flow velocity. A Primewire 
(Volcano Corporation) was placed in the LV cavity to measure pos. dp/dtmax and neg. 
dp/dtmax.  
 
Acute contractility was modulated by pacing the ventricle from different points using 
the in situ CRT device. The site of ventricular stimulation was altered allowing atrio-
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ventricular synchronous pacing from the right ventricle alone, the left ventricle alone 
and biventricularly via the epicardial pacing lead.  In 5 of the 8 patients, we also used a 
roving endocardial pacing catheter to perform LV endocardial pacing, which 
additionally allowed atrial synchronous biventricular endocardial pacing (with both a 
septal and lateral position used for the endocardial component) and simultaneous right 
ventricular endo, LV endo and LV epicardial pacing. All studies were performed with 
pacing at 10 beats above the intrinsic atrial rate to control for the Bowditch effect.127 An 
atrially paced, ventricular sensed rhythm was used as the baseline in patients with in tact 
AV nodes.  An atrially paced, right ventricular paced rhythm was used as the baseline in 
patients with AV block. 
Intracoronary adenosine was given as a bolus dose of 36 microgrammes to induce 
hyperaemia, at each pacing protocol. 
2.3 Data selection and beat analysis 
The first three to five beats recorded after a change in pacing protocol were selected for 
analysis according to our previously published protocol. A period of at least 10 seconds 
was allowed for stabilisation with each new pacing parameter. 
Signals were sampled at 200 Hz and the raw data was exported to a custom-made study 
manager programme (Academic Medical Center, Amsterdam, Netherlands) for data 
extraction of selected beats at each different condition.  Wave intensity analysis was 
then applied to the coronary data using custom-made software, “Cardiac Waves” 
(King’s College London, London, United Kingdom).  Details of the methodology used 
to perform wave intensity analysis have been previously described.69 Briefly, a 
Savitzky–Golay convolution method was adopted using a polynomial filter to refine the 
derivatives of the intracoronary pressure and velocity signals.  The selected three to five 
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consecutive cardiac cycles were gated to the ECG R wave peak, with ensemble 
averaging of aortic pressure, distal coronary pressure (Pd), Average Peak velocity 
(APV) and heart rate.  Net coronary wave intensity (dI) was calculated from the time 
derivatives (dt) of ensemble-averaged coronary pressure and flow velocity (U) as 
follows: dI=dPd/dt×dU/dt. Net wave intensity was then separated into forward and 
backward components.   
The area beneath the 4 most prominent wave intensity peaks identified were analysed 
and included in this article. These are 1) the positive, aorta-derived FCW, occurring at 
the onset of systole, 2) the negative backward compression wave (BCW) also occurring 
at the onset of systole, 3) the negative BEW, the first backward wave occurring after the 
onset of ventricular relaxation, identified by the onset of diastole and 4) the positive 
Forward Expansion Wave (FEW)(see Figure 19).  
Coronary Flow Velocity Reserve was calculated as the ratio between APV at rest and 
hyperaemia. Microvascular resistance (MR) was calculated as the ratio of the Pd and 
APV. 
We also calculated coronary perfusion efficiency (P.E).  This is a metric which 
quantifies accelerating wave energy as a proportion of total coronary wave energy 
generated by the FCW and BEW which are the waves that theoretically drive rather than 
impede coronary flow velocity.68 PE is calculated using the magnitude of the areas 
under the curve (AUCs) of the component waves  i.e. 
(FCW+BEW))/(FCW+FEW+BEW+BCW). 
Statistical analysis was performed using IBM SPSS 21.0.  Baseline demographics are 
presented as either mean & standard deviations or as proportions.  Baseline clinical 
haemodynamic data are presented as median with interquartile ranges. Normally 
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distributed data are compared using paired and independent student t-tests and non-
normally distributed data using the non-parametric equivalents.  Similarly, Pearson and 
Spearman correlation co-efficients are quoted to express associations between variables 
for normal and non-normally distributed data respectively. 
 
3.2.4 Results 
Acute contractility and coronary data were obtained in 39 different pacing settings in 
the LAD from 8 patients (see Table 4). There were no complications arising from the 
study protocol. 
 
Table 4- Demographic data 
 
Characteristics Mean (+/- S.D) or Percentage 
Age (y) 56.9 (10.6) 
Male  7/8 
QRS duration pre CRT (ms) 150.8 (23.4) 
Ejection Fraction (%) 23 (10.8) 
NYHA Class 2.7 (0.49) 
Ace Inhibitors / Angiotensin Blockers 8/8 
Betablockers 8/8 




Baseline pos. dp/dt max was 1110 mmHg/s (IQR 711 to 1177 mmHg/s) and baseline 
neg. dp/dtmax was -912 mmHg/s (IQR -861 to -1214 mmHg/s).  Baseline APV was 
17.4cm/s (IQR 13.7 to 24.7cm/s) and CFVR was 2.3 (IQR 1.5 to 2.7). 
 
Pacing via different modes led to significant variation in contractility and lusitropy. The 
percentage change from baseline in pos. dp/dtmax varied between -13% (IQR -7% to -
14%) and +10% (7.5% to 14.5%) and in neg. dp/dtmax between -15% (IQR -13% to -
22%) and +17% (IQR 9% to 33.8%).  The effect of hyperaemia on different coronary 
wave energies is shown in Table 5.  
 
Table 5-The effect of hyperaemia on the different coronary wave energies 
 
 Rest median (IQR) Hyperaemia median (IQR) 
 FCW LAD 2774 (1501 to 3614)  
p<0.01 vs hyperaemia  
5622   (3753 to 9756) 
BCW LAD 2370 (1815 to 3784)  
p<0.01 vs hyperaemia 
3703   (2178 to 5137) 
BEW LAD 7118 (4713 to 9098)  
p<0.01 vs hyperaemia 
12068 (8880 to 18103) 
FEW LAD 176   (35 to 493)            
p<0.01 vs hyperaemia 




3.2 Variation in coronary flow and LV contractility  
 
Across the range of pacing settings, there was a slight reduction in LV contractility 
(pos. dp/dtmax) with hyperaemia vs rest (1037 +/- 336 mmHg to 1056 +/- 330 mmHg, 
p=0.05) and no significant change in lusitropy (neg. dp/dtmax, -908 +/- 263 mmHg 
versus -905 +/- 261 mmHg, p=0.25).  Coronary flow velocity in the LAD increased 
significantly with hyperaemia (22.2cm/s +/- 8.6 to 45.3 cm/s +/-18.1; p<0.001) due to a 
fall in microvascular resistance from 362.5 (sd 125.5) mmHg/s/m to 156.7 (sd 50.2) 
mmHg/s/m.  Resting microvascular resistance correlated with neg. dp/dtmax (r=-0.46, 
p<0.01) but not pos. dp/dtmax r=0.25,p=0.13. There was no correlation between minimal 
microvascular resistance and contractility indices.   The comparison of coronary wave 
energies at rest and hyperaemia are shown in Table 5. 
 
3.3 Relationship between coronary wave indices and LV haemodynamics  
 
BEW magnitude correlated with the degree of contractility and lusitropy (r=0.47, 
p<0.01 and r=0.50, p<0.01 respectively) at rest. In contrast, there was no relationship 
between the magnitude of the FCW and LV indices.  The magnitude of both BEW 
and FCW at hyperaemia correlated with the degree of contractility (FCW, 
r==0.37,p=0.02;BEW, r=-0.65,p<0.01) (see  
 
 








Figure 26- The correlations between the Forward Compression Wave and Backward 
Expansion Wave with pos. dp/dtmax at hyperaemia 
 
 
BEW- Backward Expansion Wave; FCW- Forward Compression Wave 
 
 
Figure 27- The correlations between the Forward Compression Wave and the  








Perfusion efficiency (proportion of accelerating wave energy) was 76.2% +/- 7.0% at 
rest and 80.8% +/- 9.8% at hyperaemia (p= 0.04). Perfusion efficiency correlated with 
contractility and lusitropy at rest (r=0.43,p<0.01 and r=-0.50,p=0.01) and more so 
during hyperaemia (r=0.59, p<0.01 and r=-0.6, p<0.01) (see Figure 28). 
 
 
Figure 28- Increased perfusion efficiency in the LAD correlates with increased 





3.4 Summary of Main Findings: 
 
The main findings of this study are  
 
1) Ventricular stimulation from different sites is an effective means of modulating 
contractility and lusitropy in patients who have impaired left ventricular function 




2) The magnitude of the dominant accelerating wave, the BEW, and total 
accelerating wave energy correlate with the degree of left ventricular lusitropy 
and contractility.  
3) Increasing coronary flow by pharmacological hyperaemia has no acute effect on 




We believe this is the first description of a clinical model based on the simultaneous use 
of multisite pacing and adenosine induced hyperaemia to assess the effects of cardiac 
contractility and microvascular resistance on coronary wave energy.  The large changes 
in coronary flow created by directly reducing microvascular resistance have no effect on 
indices of acute contractility, although the latter have been shown to have a significant 
effect on the coronary wave intensity profile. In the previous experiment I demonstrated 
that acutely increased LAD flow velocity correlates with increased pos. dp/dtmax in CRT 
patients compared to right ventricular pacing, although the mechanistic relationship 
between LV contractility and coronary flow was unclear at that stage. The current study 
provides clarity on the causal relationship and suggests that the previously observed 
changes in LAD flow are a consequence of resynchronization rather than being a 
determinant of the acute response in LV contractility following CRT.142 It has 
previously been shown in an animal model that there is a minimum perfusion 
requirement, within the pathophysiological limits seen in vivo, to allow a positive acute 
response to CRT.35 Our data suggest that where this perfusion threshold is met, a further 




It is possibile that adenosine induced increase in flow velocity represents a distinct 
entity to the autoregulatory changes that may occur at the time of a pacing-mediated 
increase in contractility. For instance, the hyperaemic response will result in a matched 
increase in myocardial venous emptying and thus any changes in contractility as a result 
of the Gregg effect through stretch induced calcium release and increased calcium 
sensitivity may not occur. However our model is unlikely to be affected by either the 
Anrep and Gregg effect as each pacing protocol lasted for no more than 30s and both 
the Anrep and Gregg effects take longer to exert their influence on cardiac 
contractility.143 
 
Conventional interpretation of the dominant wave energy profiles in the coronary 
arteries links them to  left ventricular contractility and lusitropy. This relationship has 
previously been confirmed in vivo, in the LMCA, although most studies reporting 
changes in coronary wave energy have investigated more distal epicardial arteries.69 The 
most dominant wave is the BEW, an accelerating wave in early diastole that coincides 
with the rapid fall in ventricular pressure. We have demonstrated that the magnitude of 
the BEW is proportional to the degree of lusitropy as quantified by the neg. dp/dtmax in 
the left ventricle at rest. The fact that the BEW magnitude also correlates well with pos. 
dp/dtmax suggests that contractility and lusitropy are coupled in this population.  
 
The other important accelerating wave is the FCW, which corresponds temporally to 
peak aortic pressure and systolic coronary blood flow. While left ventricular 
contractility is a determinant of peak aortic pressure, at rest we did not find a correlation 
between pos. dp/dtmax and the FCW magnitude, suggesting that this relationship may be 
more complex as has been suggested in previous animal studies.71 Indeed, these studies 
have failed to show a strong correlation between LV contractility in the LAD and our 
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findings are in keeping with this.  An increase in the FCW has been noted in the aorta 
alongside a presumed increase in LV contractility with dobutamine but this has not been 
demonstrated in the coronary circulation and ours is the first in human experiment to 
provide a detailed examination of these relationships when contractility is being 
measured.144  
 
It may be that the lack of correlation between the FCW and contractility is due to the 
CRT model itself, in that LBBB ventricular conduction is asynchronous and as such this 
may disrupt the correlation between contractility and the FCW via the LAD.46,145 From 
the clinical perspective, it is clear that the changes in LV contractility are not the result 
of changes in coronary flow and it appears that the noted changes in WIA are a passive 
phenomenon related to changes in LV haemodynamics. 
 
At hyperaemia both the FCW and BEW correlated with both pos. dp/dtmax and neg. 
dp/dtmax.  Both the FCW and BEW are thought to be generated by changes in intracavity 
LV pressure. If one removes the insulator effects of the microvasculature with 
adenosine then the waves should better correlate with acute measures of contractility 
and lusitropy. This would be particularly the case with the BEW which “sucks” blood 
during diastole towards the LV cavity via the microvasculature from the epciardial 
arteries. If the resistance in the microvasculature is removed with adenosine then an 
impediment to this relationship is removed.  Indeed, this may account for the stronger 
correlations being seen with the BEW than the FCW as well as the improved 
correlations noted at hyperaemia. 
 
A further explanation for the better correlation of the BEW than the FCW to LV 
haemodynamics may simply relate to the differing order of magnitude of the two waves, 
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with the area under the curve of the BEW being typically 3 times larger than the FCW 
making it less prone to noise and sampling error within the experiment.  This might 
account for less pronounced and clear correlations in the data. 
Further research is therefore required to elucidate the FCW and pos. dp/dtmax  
relationship. 
 
The ratio of accelerating to decelerating wave energy can be regarded as a measure of 
myocardial perfusion efficiency and this metric has previously been applied to 
understanding altered coronary wave profiles in symptomatic aortic stenosis and in 
hypertrophic obstructive cardiomyopathy.67,68 Our data show that enhanced contractility 
and lusitropy at rest are associated with greater perfusion efficiency and that these 
correlations are stronger at hyperaemia. These findings are consistent with previous 
work that has shown biventricular pacing to be highly efficient when it increases cardiac 
contractility with favourable changes in cardiac work at minimal cost with regard to 
oxygen demand.33,34,135 It should be noted that our data show improved perfusion 




Due to the complexity of the procedure, the number of patients investigated was small 
which limits the statistical power of the study and may affect the generalizability of our 
conclusions.  This limitation applies to similar complex invasive clinical studies.72 The 
use of pos. dp/dtmax and neg. dp/dtmax to assess the acute haemodynamic response of 
CRT is well validated in CRT research.146 Whilst other measures of contractility can be 
used, the use of a conductance catheter for example would have increased the 
procedural burden to an unacceptably high level.   Furthermore, whilst peak measures 
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may vary to some extent, the variability would not be sufficient to negate our chief 
clinical finding that a significant increase in coronary flow does not result in a 
significant increase in LV haemodynamics.  Nonetheless it is important that future 
studies consider experimental methodologies that might allow other measures of 
contractility and relaxation to be assessed.  Finally, we have looked at the relationship 
between coronary haemodynamics and acute changes in contractility and lusitropy. 
Whether these conclusions can be applied to interpreting the chronic remodelling and 
long-term changes in myocardial perfusion in patients undergoing CRT needs further 
exploration. 
 
We calculated wave speed using the sum of squares method; however, during 
hyperaemia, the wave speed estimated using this method might differ from the true 
wave speed.147  
 
3.2.5 Clinical and Research Implications 
 
• Changes in coronary wave energy and flow velocity seen with different types of 
pacing do not cause changes in acute cardiac contractility but conversely, the 
changes in coronary blood flow and wave intensity are the result of changing 
contractile force. Thus whilst there may be a minimal perfusion required for 
CRT to exert its benefits, it is unlikely that treatments aimed at increasing 
coronary flow will improve ventricular function per se in patients with 
unobstructed coronary arteries.35  
 
• Varying the site and mode of pacing, using a multisite model, successfully alters 
acute left ventricular contractility and lusitropy in patients with contractile 
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dyssynchrony. This model could be used to elucidate the mechanism and 




We report the successful implementation of a novel model in heart failure patients that 
allows the acute manipulation of the two main determinants of coronary flow (LV 
contractility and microvascular resistance).   
 
Increasing coronary flow did not result in increased contractility in this cohort of 
patients with normal coronary arteries and systolic heart failure, whereas altering LV 
pacing site did.  We can conclude that any observed changes in coronary 
haemodynamics with biventricular pacing are likely a consequence of improved cardiac 
contractility from resynchronization-related cardiac output changes, rather than the 








Chapter 4 ADVANCED IMAGING AND ELECTROGRAM 
INTERPRETATION TO PREDICT RESPONSE TO CARDIAC 
RESYNCHRONISATION THERAPY AND PREDICT RISK OF 
VENTRICULAR ARRHYTHMIA 
 
4.1 SUBSTRATE DEPENDENT RISK STRATIFICATION FOR IMPLANTABLE 
CARDIOVERTER DEFIBRILLATOR THERAPIES USING CARDIAC 






The role of implantable cardioverter defibrillators in non-ischemic cardiomyopathy is 
unclear and better risk-stratification is required.   We sought to determine if T1 mapping 
predicts appropriate defibrillator therapy in patients with non-ischemic cardiomyopathy. 
We studied a mixed cohort of ischemic and non-ischemic patients to determine whether 
different CMR applications (T1 mapping, late gadolinium enhancement and Grayzone) 
were selectively predictive of therapies for the different arrhythmic substrates. 
 
Methods: 
We undertook a prospective longitudinal study of consecutive patients receiving 
defibrillators in a tertiary cardiac center. Participants underwent CMR myocardial 
tissue-characterization using T1 mapping and conventional CMR scar assessment 
before device implantation. QRS duration and fragmentation on the surface 
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electrocardiogram were also assessed.  The primary endpoint was appropriate 
defibrillator therapy.   
 
Results: 
130 patients were followed up for a median of 31 months (IQR (+/-9 months).  In non-
ischemic patients T1_native was the sole predictor of the primary endpoint (HR 1.12 per 
10ms increment in value (95% C.I 1.04-1.21; p≤0.01). In ischemic patients, 
Grayzone_2SD-3SD was the strongest predictor of appropriate therapy (HR 1.34 per 1% 
left ventricular increment in value (95% C.I 1.03-1.76;p=0.03).  QRS fragmentation 
correlated well with myocardial scar core (ROC AUC 0.64; p=0.02) but poorly with 
T1_native (ROC AUC 0.4) and did not predict appropriate therapy.   
 
Conclusions: 
In the medium-long term, T1_native mapping was the only independent predictor of 
therapy in non-ischemic patients whereas Grayzone was a better predictor in ischemic 
patients. These findings suggest a potential role for T1_native mapping in the selection of 















Implantable cardioverter defibrillators (ICD) are an effective therapy for life-threatening 
ventricular arrhythmias (VA).89  Arrhythmic risk stratification however is imperfect 
with a significant number of ICD recipients not receiving therapy.  The recently 
published DANISH trial failed to demonstrate a long-term survival benefit in a non-
ischemic, primary prevention population of patients implanted with ICDs compared 
with a matched cohort without an ICD.91 However, the study demonstrated a significant 
reduction in sudden cardiac deaths in the ICD population leading the authors to suggest 
that there is a need for better risk stratification in the non-ischemic population who 
receive an ICD under current guidelines. 148There is also growing evidence that 
ventricular tachycardia (VT) ablation may have a prophylactic role in ICD patients, 
delaying the time until VA. 149,150This may be clinically beneficial as appropriate ICD 
therapies have been shown to be a bad prognostic indicator.151 Improved risk 
stratification of VA in patients prior to ICD implantation is therefore desirable as it may 
enhance patient selection with regard to both device eligibility and suitability for 
prophylactic VT ablation. 
 
Cardiac Magnetic Resonance Imaging (CMR) has the potential to improve this risk 
stratification; it can identify areas of myocardial scar which act as substrate for VA in 
both ischemic and non-ischemic cardiomyopathy (ICM & NCM).95,103,152 Patients with 
ICM often have regional fibrosis while NCM patients may exhibit a more diffuse 
pattern of fibrosis.153 Advanced tissue characterisation by CMR to assess the peri-
infarct region or Grayzone has been shown to predict VA in ICM patients.98 Diffuse 
myocardial fibrosis acts as potential VA substrate in NCM and can be quantified non-
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invasively using CMR protocols such as T1 mapping. 80,81,154Native T1 mapping 
(T1_native ) using CMR allows the quantitative assessment of myocardial tissue in vivo 
without the administration of contrast and is elevated in the presence of edema, diffuse 
fibrosis and myocardial scarring.  The T1_native value is thus an inherent tissue- specific 
property and these values have been shown to be highly effective in differentiating 
healthy myocardium from diffusely diseased tissue.155 We have previously 
demonstrated that T1 mapping predicts appropriate ICD therapy in a mixed cohort of 
ICM and NCM ICD patients at 15 month mean follow up.101 It is not clear whether 
T1_native remains predictive of VA in the medium to long term in ICD patients and 
whether the different MRI protocols assessing focal and diffuse fibrosis have specific 
value for ICM and NCM respectively. 
 
Given the pathophysiological mechanisms of VA, we hypothesized that Grayzone 
assessment would be the most powerful predictor of VA in the ICM population whereas 
T1 mapping would be the most powerful predictor of VA in NCM patients. We also 
hypothesized that non-invasive markers such as surface ECG fragmentation (fQRS) 




Consecutive patients undergoing ICD implantation for primary and secondary 
prevention between May 2011 and January 2013 in our hospital were invited to 
participate in this prospective study.  All patients were on optimal medical therapy 
including anti-arrhythmic therapy as per their attending cardiologist. The study protocol 
was approved by the South London Research Ethics Committee and conducted in 
accordance with the Declaration of Helsinki.  All study participants underwent CMR 
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assessment and coronary angiography before device implant.  Ischemic etiology was 
defined by standard criteria (presence of any epicardial coronary artery stenosis >75%, 
prior history of myocardial infarction or coronary revascularization with a scar pattern 
consistent with myocardial infarction on CMR imaging) and NCM by the absence of the 
above criteria 
 
4.1.3.1 CMR imaging protocol and analysis: 
 
The details of the CMR protocol are described in the Methods section. In brief, CMR 
imaging was performed using a 1.5-T scanner with a 32-channel coil (Philips 
Healthcare, Best, The Netherlands). Contrast injection (gadobutrol 0.2mmol/kg body 
weight) was used for CMR scar assessment from which scar indices were calculated 
using both the 2-standard deviation (SD) method (Scar_2SD), (defined as the region with 
signal intensity (SI) 2 SD above the remote reference myocardium) and the full-width 
half-maximum (FWHM) method (Scar_FWHM), defined as the region with SI above the 
50% of the maximal SI of the enhanced area.  To determine the extent of scar 
distribution we also extended the 2-standard deviation method up to 6 standard 
deviations (see Figure 29).  The extent of the Grayzone was quantified as previously 
described.156 Both the Grayzone and scar indices were indexed as a percentage of LV 










Figure 29- Acquisition of Grayzone and native T1 data. 
 
 
Left panel: A late gadolinium mid-ventricular slice CMR demonstrating the acquisition of scar data using 
the Standard Deviation (SD) technique. Note the remote reference point and diminishing size of scar as 
SD increases.  Right panel: A T1 map of a mid-ventricular CMR slice with a mid-septal region of interest 
used for analysis. 
 
A single mid ventricular short-axis slice (in the same geometry as the mid-ventricular 
CMR slice) was acquired for T1 mapping both before and after the administration of 
contrast using a modified Look-Locker inversion-recovery sequence with 11 phases 
(3+3+5) (repetition time/echo time = 3.3/1.5ms; flip angle =50°; voxel size = 1.8 x 1.8 x 
8mm; with heart rate adapted trigger delay and adiabatic prepulse to achieve a complete 
inversion) (see Figure 29).  Two independent CMR experts blinded to the study endpoint 
evaluated the CMR images separately.  Discrepancies were adjudicated by joint 
discussion. 
 
4.1.3.2 ECG Protocol- Assessment of fragmentation 
 
The details of ECG assessment are described in the Methods section.  Briefly, standard 
12-lead ECGs recorded at the standard sweep speed of 25 mm/s were collected prior to 
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device implant. These were analysed by two cardiologists blinded to patient 
characteristics and endpoints to assess for fQRS.  In case of discrepancy, the data were 
jointly reviewed with a third expert to reach a consensus.  The assessment of fQRS was 
performed according to previously published criteria with QRS duration >120ms 
differentiating wide from narrow for the purposes of fQRS analysis.108,109 This allowed 
assessment of fQRS as a categorical variable for all QRS durations. 
 
4.1.3.3 Follow up Endpoints 
 
All patients underwent ICD or Cardiac Resynchronization Therapy-Defibrillator 
implantation. A standardized program for VA detection and therapy was used.101 (VA 
>170 beats/min with detection count >16 intervals received Anti-Tachycardia Pacing 
(ATP) and then shock therapy if ATP failed. VA> 210 beats/min, detection count: 24/30 
intervals were treated with shock therapy.  Standard supraventricular tachycardia 
detection discriminators were enabled according to the recommendations of device 
manufacturers (St Jude Medical Inc, St Paul, MN and Medtronic, Minneapolis, MN; 
onset: 81% for Medtronic devices and 18% for St Jude Medical devices; stability: 40ms 
for both types of device; morphology: passive.)  Patients were followed up at 3-month 
intervals and at each follow-up an experienced device physiologist reviewed any 
recorded events with an electrophysiologist with both investigators blinded to the CMR 
data.  Remote monitoring was applied where available and patients were encouraged to 
perform downloads if they felt symptomatic or thought they had received a therapy.  
Downloads were reviewed in the same manner as the standard follow ups and patients 
were asked to attend pacing clinic urgently where therapy had been applied.  Death was 
ascertained by review of hospital medical records and if there was concern about loss of 




The primary endpoint was the delivery of appropriate ICD therapy for VT or ventricular 
fibrillation.  A composite secondary endpoint of appropriate therapy or death was also 
assessed. 
 
4.1.4 Statistical Analysis 
 
Continuous demographic variables are shown as the mean ± SD; time to events are 
shown as median ± Inter quartile range (IQR) and categorical variables are shown as 
percentages. The unpaired Student's t-test was used to compare normally distributed 
continuous variables; otherwise the Mann-Whitney U or Wilcoxon test was used. 
Categorical variables were compared using the χ2 test. The 95% confidence interval 
(CI) was determined on the basis of the normal distribution of variables. The first 
episode of appropriate therapy or death was considered as the event of interest for 
quantifying various associations depending upon the endpoint being assessed. Cox 
proportional hazard regression analyses were performed to assess the univariable and 
multivariable adjusted association between pre-specified variables and the primary 
endpoints.   For multivariable-adjusted analyses, a forward selection process using only 
variables significantly associated with the outcome of interest in univariable analyses (at 
p<0.05) was used to further determine any independent predictors of the primary 
endpoint. All reported associations in this study are hazard ratios (HRs) with their 
corresponding 95% confidence intervals. Only patients who had complete information 
on CMR–derived indices and T1 mapping–derived indices were included in 




The multivariable adjusted analysis studied each of the CMR indices that rely on late 
gadolinium enhancement  (scar, Grayzone and midwall-fibrosis (NCM only)) separately 
to avoid confounders and limit the number of variables in each model.  T1_native and 
T1_post were analysed as continuous variables with HRs reported for every 10ms 
increment increase in T1 value. Both the Grayzone and scar indices were indexed as a 
percentage of LV mass and analysed as continuous variables and HRs calculated for 
every 1% increase. 
 
Receiver operating characteristics (ROC) curves using T1_native and Grayzone_2SD-3SD 
were plotted to identify variable cut-off points with 90% sensitivity to discriminate the 
primary endpoint. The estimated cut-off values were retrospectively used to reclassify 
and dichotomize the study subjects into high-and low-risk categories determined by 
whether subjects had met the primary endpoint. Kaplan-Meier survival curves were then 
plotted to study the cumulative event rates between groups of participants, with the log-
rank test providing further evidence regarding any significant differences between them.  
All the above analyses were performed for the total population and for each etiology 
separately.   All data analyses were performed using SPSS statistical software (version 




A total of 130 patients were recruited, 72 with ICM (55.4%) and 58 with NCM (44.6%).  
Etiologies of the NCM cohort were 52/58 idiopathic dilated cardiomyopathy, 5/58 with 
hypertrophic cardiomyopathy and 1/58 with sarcoidosis).   Of the entire cohort 93/130 
ICD recipients (71.5%) were implanted with an ICD for a primary prevention 
indication. All patients’ imaging was analyzed for Grayzone and scar core. One hundred 
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study participants underwent T1 mapping and, of this subset, 95 paired native and post 
contrast T1 mapping images were suitable for analysis. Due to a number of clinical 
considerations such as claustrophobia, lack of contemporaneous haematocrit and poor 
breath-holding technique the remaining 30 patients did not have T1 mapping in 
additional to conventional late gadolinium enhanced scar images. 
 
Demographic data is presented by etiology (ICM and NCM) and is shown in Table 6. 
Patients with NCM were younger (p<0.05) and were less likely to have QRS 
fragmentation than ICM patients (p<0.01). The ICM population had significantly 
increased markers of regional fibrosis (Grayzone and scar core burden) compared with 
the NCM cohort (Grayzone_FWHM 10.07±4.83 vs 6.51±6.02, Scar_2SD 24.95±8.98 vs 
14.98±13.28 , all p=<0.001) In contrast there was no statistical difference in the T1_native 
values between ICM and NCM patients (1054±7.15 vs 1073±7.55.p=0.18).  
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Table 6- Demographic data by aetiology 
 
 
4.1.5.1 Primary Endpoint 
 
During a median follow-up period of 938 days (IQR 672 to 1192 days), 36 patients 
(27.7 %) experienced the primary endpoint. The median time to first ICD therapy was 
329 days (IQR 116 to 532 days). The proportion of those meeting the primary endpoint 
129 
 
was greater in the secondary prevention group (16 of 37 (43.2%)) than in the primary 
prevention group (20 of 93 (21.5 %);p =0.01).  The cumulative event rate was similar 
between ICM and NCM patients (18 of 72 (25%) and 18 of 58 (31.0%); p=0.43).  Of 
the 18 ICM patients meeting the primary endpoint 7/18 patients were treated for 
ventricular fibrillation and 11/18 for VT (mean heart rate 196bpm).  Of the 18 NCM 
patients meeting the primary endpoint 8/18 patients were treated for ventricular 
fibrillation and 10/18 for VT (mean heart rate 199 bpm).  The median time to first 
appropriate therapy was similar for both etiologies (NCM- 335 days (IQR 171 to 537 
days), ICM- 287 days (IQR 67 to 481 days); p=0.44.)  With regard to the secondary 
endpoint, 56 patients experienced either appropriate therapy or died (44% ICM, 35% 
NCM; p=NS). 
 
4.1.5.2 Predictors of Primary and Secondary Endpoints in the combined ICM and NCM 
cohort 
 
The results of univariable and multivariable adjusted analyses for the primary and 
secondary endpoints in the entire cohort are shown in Table 7. MRI indices of regional 
(scar and Grayzone) and diffuse fibrosis (T1_native mapping) were independently 
associated with ICD therapy. The same CMR indices were also independently 
associated with the secondary endpoint. Extra Cellular Volume (ECV) and fQRS did 
not predict either endpoint.  
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Table 7- Univariable and multivariable analysis for primary and secondary endpoint 
 




4.1.5.3 Predictors of appropriate therapy according to aetiology 
 
ICM: The results of univariable and multivariable adjusted analysis in ICM group for 
the primary endpoint are shown in Table 8 and Table 9 respectively. T1_native, scar and 
Grayzone remained predictive of the primary endpoint in multivariable adjusted 
analysis. fQRS did not predict occurrence of the primary endpoint in multivariable 
adjusted analysis.  With regard to the secondary endpoint, at multivariable adjusted 
analysis scar and Grayzone indices remained predictive however T1_native was not (See 
Table 8). 
 





Table 9 - Multivariable adjusted analysis for primary endpoint split by aetiology 




NCM: The results of univariable and multivariable adjusted analysis in NCM group for 
the primary endpoint are shown in Table 9 and Table 10.  Whilst univariable analysis 
revealed a significant association between the primary endpoint and secondary 
prevention, Grayzone_2SD-3SD, Grayzone_FWHM, Scar_2SD, Scar_3SD and T1_native, 
multivariable adjusted analysis revealed that only T1_native was independently associated 
with the primary endpoint.  With regard to the secondary endpoint only T1_native 
remained predictive following multivariable adjusted analysis (See Table 9). 
 
Table 10- Univariable analysis for primary endpoint:  NCM only 
 
 
4.1.5.4 Post hoc risk re-stratification according to aetiology 
ROC analysis suggested the use of Grayzone_2SD-3SD  >4.0% of left ventricular mass and 









When applied to the mixed cohort both the T1 and Grayzone cut-off significantly 
identified patients at increased risk of reaching the primary endpoint but both also failed 
to identify a significant minority of patients who went on to meet the primary endpoint 
despite being dichotomized into proposed low risk cohort. (see Kaplan-Meier curves in 
Figure 30) 
 
Figure 30- Post hoc analysis using either Grayzone_2SD-3SD  and a retrospectively applied 
cut-off of >4% of LV mass or T1_Native and a retrospectively applied cut-off of >1003ms 






16 of the 54 patients (29.6%) who did not experience the primary endpoint were 
reclassified into low risk based on a dichotomizing cut off of Grayzone_2SD-3SD >4.0% of 
left ventricular mass.  All of the 18 patients who met the primary endpoint remained 
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classified as high risk using this cut-off (Log rank test 6.2; p=0.01, see Kaplan-Meier 
curve in Figure 31). 
 
Figure 31- Post hoc analysis using Grayzone_2SD-3SD and a retrospectively applied cut-
off of >4% of LV mass to dichotomize ICM patients into high and low risk (Log rank 




On the basis of T1_native using a cut-off of 1003ms, 16 of the 40 participants (40%) were 
correctly reclassified into the low-risk category as they had not met the primary 
endpoint.   3 out of 14 patients (21.4%) who had met the primary endpoint were 




NCM: In the NCM group, 8 of the 27 patients (29.6%) who did not meet the primary 
endpoint were reclassified into low risk based on retrospective application of T1_native 
cut-off and all 14 patients experiencing a positive endpoint remained in the high risk 
cohort (Log rank Chi-Square 4.8; p=0.03, see Kaplan-Meier curve in Figure 32). Using 
the Grayzone_2SD-3SD cut-off, 24 out of 40 patients (60%) who did not meet the primary 
endpoint were risk restratified as low risk.  However the Grayzone cut-off also 
reclassified 6 out of 18 patients (33.3%) who met the primary endpoint as low risk. (Log 
rank Chi-Square 4.0; p=0.05) 
 
Figure 32- Post hoc analysis using T1_Native and a retrospectively applied cut-off of 








Using T1_native to risk stratify NCM patients and Grayzone_2SD-3SD to risk stratify ICM 
patients the net reclassification of high risk to low risk is 29.6% without reclassification 
of any patients incorrectly to low risk. 
 
4.1.5.5 Risk re-stratification in primary prevention patients 
 
In the primary prevention cohort 20 of the 93 participants (26.6%) with a primary 
prevention ICD who failed to meet the primary endpoint were correctly reclassified to 
the low-risk group on the basis of the Grayzone cut-off, while two patients with a 
positive endpoint were mistakenly reclassified into the low-risk group. 20 of the 51 
patients (40%) who had an ICD implanted but did not experience the primary endpoint 
were correctly reclassified into the low-risk category on the basis of T1_native cut-off, 
while again two of the participants experiencing a positive end point were mistakenly 
reclassified into the low-risk group.   
 
However, using the T1 cut-off only for the NCM primary prevention patients, 6/22 
(27.3%) patients who did not reach the primary endpoint were correctly reclassified to 
low risk whilst the 8 patients who received appropriate therapy remained as high risk.  
There were no reclassifications of patients who met the primary endpoint to low risk.   
 
Equally, using the Grayzone cut-off for primary prevention ICM patients 11 out of 39 
(28.2%) patients were reclassified as low risk without any of the 10 patients who met 






4.1.5.6 Relationship of fQRS with regional and diffuse fibrosis 
 
The Receiver Operator Curves (ROC) assessing the relationship between T1_native, 
Grayzone_3SD-2SD and Scar_2SD with fQRS had Areas under the Curve (AUC) of 0.4, 
0.56 and 0.59 respectively.  The difference between the AUC for T1_native and Scar_2SD 
was significant (z score -2.34, p=0.02).  Further post hoc analysis showed an increasing 
AUC and thus improved association with fQRS by increasing the Scar_(X)SD value up to 
Scar_6SD suggesting a correlation between fQRS with more homogeneous scar core than 
with heterogeneous Grayzone. However this correlation did not reach a significant level 
(see Figure 33, Z score 0.6, p=0.55). 
 
Figure 33- The relationship between scar core and increasing AUC for relationship 
with fragmented QRS 
 
 
As the signal intensity of defined scar core increases  (2 standard deviation method up to 6 standard 
deviation method) so the proportion of scar as a percentage of LV mass falls and the relationship with 




4.1.5.7 Reproducibility of T1 mapping 
 
T1 measurements were repeated in a subgroup of randomly selected patients from the 
study cohort (10 with NCM and 10 with ICM). For T1_native measurement, the 
intraobserver average difference in values was 5 ± 3ms and the coefficient of variation 
was 0.3% ± 0.2%; the interobserver average difference in values was 6 ± 5 ms and the 
COV was 0.4% ± 0.3%.  
4.1.6 Discussion 
 
The present study extends our previous findings of the independent predictive value of 
T1_native for appropriate ICD therapy in patients with both ICM and NCM from the short 
to the medium- long term.  More interestingly, by dichotomizing patient by etiology we 
show for the first time that T1_native is the only independent predictor of appropriate 
therapy in patients with NCM and demonstrate the powerful predictive value of 
Grayzone in ICM.   
 
The study is the first to incorporate supposed clinical predictors of VA (fQRS) and 
advanced CMR techniques in the same patient cohort and clearly shows the superiority 
of the CMR indices over fragmentation. The study demonstrates that fQRS is not a 
correlate of diffuse fibrosis, but may be more related to scar core. 
 
4.1.6.1 CMR indices and aetiology 
 
The T1_native value was the only predictor at multivariable analysis of the primary 
endpoint and secondary endpoints in the NCM cohort.  In contrast, in the ICM cohort, 
indices of scar and Grayzone as well as T1_native were predictive of the primary 
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endpoint.  However, the T1_native value was not predictive of the secondary endpoints in 
the ICM cohort whereas indices of scar and Grayzone continued to remain significant. 
 
Taken together these findings are consistent with the differing pathophysiological 
features of the two etiologies.  VA in ICM is related to sub-endocardial scar following 
infarction with a peri-infarct Grayzone offering a potentially highly arrhythmogenic 
substrate.98 It is therefore unsurprising that across all endpoints the measures of scar and 
Grayzone remain independent predictors of VA in ICM.  Conversely, NCM is 
characterized by diffuse fibrosis and it is consistent therefore that T1_native should remain 
predictive of VA across all endpoints whereas scar and Grayzone are not. 80,157 
 
4.1.6.2 Fragmented QRS 
 
We found no evidence that the presence of fQRS offers any predictive value for VA.  
Our findings are in keeping with previously published work in a similar ICD patient 
population which showed a trend towards increased arrhythmic risk in patients without 
fQRS.110 Our CMR analysis allows us to further characterize what pathophysiological 
features fQRS may represent.  Contrary to our hypothesis that fQRS represents areas of 
peri-infarct tissue or diffuse fibrosis, the ROC analysis seems to suggest that 
fragmentation relates to scar core (which accords with our analysis of scar core and 
arrhythmic risk). 
 
4.1.6.3 Comparison with previous studies 
 
The ability of T1 mapping to predict ICD therapy in NCM is in keeping with a recent 
publication from our institution demonstrating the ability of native T1 mapping to 
predict mortality in NCM.102 Further to Puntmann et al’s findings, our results 
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demonstrate the predictive role of native T1 mapping in a significantly higher risk group 
of NCM patients with a much higher event rate.  
 
4.1.6.4 Clinical Implications of risk restratification 
 
The risk re-stratification data has two potential clinical implications:   
First, the Grayzone cut-off value used for ICM and the T1_native cut-off value used for 
NCM create a cohort in whom VA is unlikely. This offers the possibility to further risk 
stratify patients who would currently receive an ICD into a lower risk cohort.  This is 
particularly pertinent in the NCM group:  The recently published DANISH study failed 
at 6-7 years to demonstrate a survival benefit with ICDs in a non-ischemic cohort 
despite a reduction in sudden cardiac death.91 Importantly, the survival curves merged at 
the end of the study having previously suggested a trend towards benefit in those 
implanted with an ICD whereas the risk reduction for sudden death with an ICD began 
to emerge at 2 years and persisted throughout the study.  Thus, there may be a medium-
term survival benefit using ICD in NCM patients which may warrant ICD implantation, 
particularly if a cohort of patients at risk of sudden death and VA can be correctly 
identified.   T1 mapping is potentially such a tool with a powerful predictive value for 
VA and a biologically plausible underpinning to substantiate its use.  Identification of 
these patients would also highlight them as being at generally high risk of death from 
other causes in the medium to long term. 
  
Secondly the risk re-stratification analysis may be used to identify which patients 
remain at high risk of VA.  This is of particular interest in the ICM cohort where there is 
growing interest in prophylactic VT ablation. 150,158,159 Patient selection for VT ablation 
remains a controversial area with some centres advocating ablation in all patients 
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receiving an ICD with other centres choosing to ablate only in incessant drug refractory 
VT.   The cut-offs used in our study could be used to select patients for prophylactic VT 
ablation particularly in the primary prevention cohort where both T1_native and Grayzone 
reclassified a significant number of patients correctly to low risk with only a small 
number of patients (3 and 2 respectively) incorrectly classified to low risk.  
 
In contrast to using the cut-offs as decision aids for ICD implantation, there is less 
clinical significance to the incorrect reclassification of patients to low risk when 
considering suitability for VT ablation as there is no denial of proven life-saving 
therapy.   
 
4.1.7 Study Limitations 
 
Whilst representing a relatively unselected cohort of patients (channelopathies were 
excluded) the sample size is not sufficiently large to draw firm conclusions and there is 
a need for further work to validate these results in larger, randomised studies.  The 
absolute T1 values of interest can be influenced by a number of technical parameters 
including magnetic field strength and acquisition sequence as well as post- acquisition 
image processing including motion correction and image registration. T1 mapping was 
limited to just a single slice of myocardium and an assumption made that the tissue 
characterized in the region of interest was representative of the remote myocardium.  
This methodology has been previously shown to increase T1 mapping reproducibility 
and, as noted above, there was a high level of inter and intra-observer reproducibility. 
154Conducting a single-center study allows standardization of the imaging protocol; 
however, it may have introduced systematic bias making adoption of cut-off values in 
other centers potentially misleading. Nonetheless there is now evidence that T1 
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mapping protocols can be reproduced across multiple centers with low inter and intra-
observer variability. A separate validation cohort is needed to verify the values derived 
from the AUC analysis of T1native and Grayzone2SD-3SD for prediction of the primary 
endpoint before these values should be used in clinical practice. However, work from 
our institution has previously shown at 1.5 Tesla in the healthy human heart a mean 
T1native of  950ms ± 21ms (Upper limit using 2 standard deviations- 992ms) which 
would suggest our T1 cut-off of 1004ms is plausible.  
The device programming represents our institution’s preferred therapies in 2011 when 
the study began.  However the MADIT-RIT study demonstrated the benefits of less 
aggressive programming and this has resulted in changes to our current practice.160 It 
may be that the effect size is thus overstated as some tachyarrhythmias may have self-
terminated with less aggressive programming, however many patients had VF initially 
and others recurrent VT suggesting that our results remain valid.  
95/130 patients had T1 images that were suitable for analysis.  However, we do not 
believe it likely that failure to obtain these images in the 3 remaining patients resulted in 
any significant bias.  It is likely as CMR continues to evolve that shorter acquisition 
times will allow greater patient tolerance of more complex protocols. 
4.1.8 Conclusion 
 
In the medium to long-term, T1 mapping appears to be a powerful predictor of VA in 
NCM whereas Grayzone is a stronger predictor in ICM.  Both indices outperformed 
fQRS in the prediction of VA.  Both T1 mapping and Grayzone have the potential to 
refine ICD implantation decisions and also to inform patient selection for VT ablation 





4.2 THE RELATIONSHIP BETWEEN VECTORCARDIOGRAPHY AND 





Background: Vectorcardiography (VCG) parameters and myocardial scar both affect 
cardiac resynchronization therapy (CRT) response. The purpose of this study was to 
investigate the relationship between VCG and myocardial scar, defined by cardiac 
magnetic resonance (CMR) imaging, and whether combining these metrics may 
improve CRT response prediction.  
 
Methods: Consecutive patients referred for CRT who underwent pre-procedural CMR 
were included. VCGs were synthesized from electrocardiograms using the Kors 
transformation matrix. QRS duration (QRSd), QRSarea and Tarea were derived from the 
VCG. CMR parameters reflecting regional focal scar core (Scar2SD) and scar border 
zone (Gray2SD), and diffuse fibrosis (pre-T1, extracellular volume [ECV]) were 
assessed. CRT response was defined as echocardiographic reduction in left ventricular 
end-systolic volume (ΔLVESV) of ≥15% after six months follow-up.   
 
Results: Thirty-three patients were included, of whom 58% were CRT responders. 
Scar2SD and Gray2SD inversely correlated with VCG parameters, whereas pre-T1 and 
ECV did not show a significant correlation with VCG parameters. QRSarea showed the 
strongest association with Scar2SD (R=-0.58, p<0.001). Receiver operating 
characteristics curve (ROC) analyses showed that Scar2SD, Gray2SD and QRSarea 
predicted CRT response with AUCs of 0.692 (CI: 0.503-0.881, p=0.063), 0.759 (CI: 
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0.586=0.933, p=0.012) and 0.737 (CI: 0.564-0.910, p=0.022) respectively. A combined 
ROC derived cut-off threshold for Scar2SD and QRSarea resulted in a CRT response 
percentage of 92% for patients with large QRSarea and small Scar2SD or Gray2SD.  
 
Conclusion: QRSarea on the VCG is inversely associated with focal scar burden, but not 
diffuse fibrosis, on CMR. The interaction between focal scar and VCG, combined 




CRT is an effective treatment for patients with symptomatic heart failure (HF), reduced 
systolic left ventricular (LV) function, and wide QRS complex.  Nevertheless, about 
one-third of patients eligible according to current guidelines fail to benefit from CRT. 
Suboptimal CRT response has been attributed to factors including QRS duration 
(QRSd) <150 ms, non-left bundle branch block (non-LBBB) morphology, ischemic 
cardiomyopathy, and suboptimal LV lead position. 27,104,161 
 
Objective parameters, derived from the three-dimensional (3D) vectorcardiogram 
(VCG), have been shown to more accurately predict CRT response than QRSd or 
morphology.162 The VCG represents the electrical heart vector in three orthogonal 
directions (X, Y, and Z) and can be derived from a true VCG lead system or synthesized 
from the standard 12-lead ECG using a mathematical transformation matrix.120 The 3D 
area of the VCG QRS- (QRSarea) and T-loop (Tarea) are supposed to reflect unopposed 
electrical forces during ventricular depolarization and repolarization respectively. Both 
QRSarea and Tarea have been shown to be strong predictors for LV reverse remodeling 
after CRT.85,162 In a single small study it was observed that QRSarea was relatively 
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reduced in patients with ischemic cardiomyopathy, suggesting an association between 
QRSarea  and myocardial scar. 163 
 
Ischemic cardiomyopathy, the presence and size of scar burden, and positioning the LV 
lead in scar are negatively associated with CRT outcome.85,94,164 CMR is able to 
characterize different types of myocardial scar including focal scar with LGE and 
diffuse fibrosis with T1 mapping. Recent work demonstrated that focal scar, but not 
diffuse fibrosis, was associated with poor CRT response.76 
 
Summarizing the above literature, it appears that an electrical substrate and low 
myocardial scar burden is favorable for response to CRT. The association between the 
electrical substrate as measured by VCG and myocardial scar as measured by CMR is 
however not known.  
 
The purpose of this study was therefore to investigate 1) the association between VCG 
parameters and myocardial scar (both focal and diffuse) on CMR in HF patients with 
ventricular conduction disturbance, and 2) whether combining VCG with CMR scar 




4.2.3.1 Study population 
 
Consecutive patients referred for CRT device implantation who underwent CMR 
imaging as part of their clinical workup were prospectively enrolled at Guys and St 
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Thomas’ NHS Trust hospital as previously described. The South-East London Research 
Ethics Committee approved the study protocol and all patients gave written consent.  
 
4.2.3.2 Vectorcardiography analysis 
 
Standard 12-lead ECG’s were recorded prior to CRT implantation in supine position 
using the ECG machine MAC 5500 HD (GE Healthcare, Chicago, IL). The digital PDF 
ECG files with vector graphics were used to extract the original digital ECG-signal. 
VCGs were semi-automatically synthesized from these digital ECG signals using 
custom software programmed in MATLAB.85 The Kors transformation matrix was used 
to transform the 12-lead ECG to VCG.120 The onset and end of the QRS-complex and 
T-wave were manually set on the three overlaid orthogonal leads (X, Y, and Z) of the 
VCG by two electrophysiologists blinded to CRT outcome. QRSarea and Tarea were 
defined as the 3D areas of respectively the QRS- and T-wave loop from the VCG 
between the loop and baseline in X, Y, and Z direction calculated as QRSarea = 
(QRSarea,x + QRSarea,y  + QRSarea,z)1/2,  Tarea  = (Tarea,x + Tarea,y + Tarea,z)1/2.85,163  
 
4.2.3.3 CMR analysis 
 
CMR Imaging Patients underwent CMR prior to their CRT implantation using a 1.5T 
scanner with a 32–channel coil (Philips Healthcare, Best) as described above. Two 
independent CMR experts, blinded to CRT outcome, assessed the CMR images. In case 
of discrepancy, consensus between the reviewers was reached. LV mass was quantified 
using CVI 42 (Circle Cardiovascular Imaging Inc, Calgary) software and used to index 
the LGE quantification of focal scar. The extent of Scar core was quantified using the 2-
standard deviation (2SD) method, defined as the region with signal intensity (SI) >2SD 
above reference myocardium (Scar2SD). The extent of Gray zone was quantified by the 
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difference in SI between Scar2SD and Scar3SD (Gray2SD). All LGE scar parameters were 
expressed as a percentage of LV mass (%LV). T1 relaxation maps were processed using 
a customized software plugin with Osirix (Pixmeo, Geneva), from which the diffuse 
fibrosis parameters pre-contrast T1 (pre T1) and extracellular volume index (ECV) was 
calculated.  
 
4.2.3.4 CRT implantation and response 
 
The LV lead was preferentially targeted to a postero-lateral, lateral or anterolateral 
coronary sinus tributary, with pacing sites preferentially chosen in a basal position 
remote from CMR scar. Trans-thoracic echocardiography was assessed pre- and six 
months post-CRT implantation using a GE Vivid 7 scanner (General Electric-Vingmed, 
Milwaukee, Wisconsin). Standard 2D images of LV dimensions and ejection fraction 
(LVEF) were acquired in standard apical 2- and 4-chamber views. LV end-diastole and 
end-systole volumes (LVEDV, LVESV) were used to estimate LVEF using the 2-
dimensional modified biplane Simpson’s method (EchoPac 6.0.1, General Electric 
Vingmed). CRT response was defined as an echocardiographic LVESV reduction of 
≥15% of baseline afters six months follow-up.  Echocardiography was performed by 
sonographers blinded to both VCG and CMR data. 
 
4.2.4 Statistical analysis 
 
Statistical analyses were performed using SPSS 24.0 (SPSS Inc., Chicago, Illinois) and 
MATLAB (Matlab 2016B, MathWorks, Natick, MA). Continuous variables are 
expressed as mean±SD or median and interquartile range (IQR) and dichotomous 
variables in frequencies and percentages. Spearman correlation analyses were carried 
149 
 
out between and within VCG and CMR parameters. Parameter differences between 
CRT responders vs. non-responders were compared using Mann Whitney U-tests. 
Receiver operating characteristics (ROC) curves were generated to evaluate the 
diagnostic accuracy of all parameters in identifying CRT response and to find optimal 
cut-off values. These cut-off values were used to dichotomize the population to groups 
≤cut-off and >cut-off, and the number of CRT responders for every subgroup were 
compared using Chi-squared analyses. The most promising VCG and CMR scar 
parameters were combined in a cross-tab to evaluate its joint effect on CRT response 
prediction. Differences within the crosstabs were evaluated using Fisher’s exact tests. 




Thirty-three consecutive patients with either non-ischemic (n = 17) or ischemic (n = 16) 
cardiomyopathy were included. Patient characteristics are provided in Table 11, 
showing a typical CRT population.  
 
Table 11- Baseline demographic data 
 
Demographics  
 Total patient no.   33 
 Age (years) 65±12 
 Male 27 (82%) 
 Ischemic cardiomyopathy  16 (49%) 
 NYHA (II/III/IV)  1 (3%) / 31 (94%) / 1 (3%) 
 CRT with ICD 31 (94%) 
 Posterolateral scar  22 (67%) 
 LVEF (%)  24±8 
 ECG QRS duration (ms) 150±22 
 ECG LBBB  12 (36%) 
 CRT response (LVESV ≥15)  19 (58%) 
 
Values are displayed as mean and standard deviation or n (%). BMI=body-mass-index, 
EDV=end-diastolic volume, ESV=end-systolic volume, LBBB=left bundle branch block, LV=left 




4.2.5.1 Association between VCG and myocardial scar 
 
Scar2SD and Gray2SD inversely correlated with the VCG parameters. From the diffuse 
fibrosis parameters, there was only an inverse correlation between ECV and QRSd, 
while there was no association between diffuse fibrosis and QRSarea or Tarea (see Figure 
34).  
 
From the VCG parameters, QRSarea had the strongest correlation with focal scar, while 
QRSd showed the lowest correlation. From the LGE parameters, the strongest (inverse) 

















Figure 34- Scatter plots of CMR scar parameters vs. VCG parameters. Correlation 




All focal scar CMR parameters correlated inversely with the ECG/ VCG parameter. 
 
 
QRSarea correlated strongly with Tarea (R: 0.847, p<0.001) and to a lesser extent also 
with QRSd (R: 0.415, p=0.016). There was a strong correlation between Scar2SD and 
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Gray2SD (R: 0.869, p<0.001), while Scar2SD did not correlate with pre-T1 or ECV 
(p=0.505 and 0.136 respectively).  
 
4.2.5.2  CRT response 
 
Nineteen out of 33 patients (58%) showed a reduction in LVESV of ≥15% after six 
months follow-up and were therefore defined as CRT responders.  
 
Scar2SD and Gray2SD were lower in CRT responders than in non-responders, although 
only significant for Gray2SD (p<0.011).  Pre-T1 and ECV however did not differ 
between CRT responders and non-responders (p=0.152 and 0.706, respectively). 
QRSarea, but not Tarea, was significantly higher in responders than in non-responders to 
CRT (p=0.021) see (Table 12). 
 
Table 12- Parameter value differences between responders and non-responders to 
CRT 
 	 	 CRT	non-responders	(n=14)	 CRT	responders	(n=19)	 p-value	T1	mapping	(diffuse	fibrosis)	 	 		 Pre-T1	(ms)	 1063	(984-1098)	 1065	(1002-1105)	 0.706		 ECV	(%)	 0.33	(0.29-0.37)	 0.29	(0.24-0.35)	 0.152		 	 	 	 	LGE-CMR	(focal	scar)	 	 		 Gray2SD	(%)	 7.27	(5.48-10.37)	 3.83	(1.69-6.10)	 0.011*		 Scar2SD	(%)	 26.16	(18.69-28.84)	 13.29	(4.55-26.83)	 0.065		 	 	 	 	VCG	parameters	 	 	 		 QRSd	(ms)	 145	(125-161)	 151	(144-168)	 0.199		 QRSarea	(mV.ms)	 59	(33-78)	 106	(62-163)	 0.021*		 Tarea	(mV.ms)	 41	(32-63)	 42	(25-90)	 0.577	
 
Responders are defined as reduction of LVESV ≥15%. P-values are based Mann Whitney u-
tests. Continuous variables are displayed as median and interquartile ranges. *indicates 




4.2.5.3 ROC analyses for CMR and VCG parameters identifying CRT response 
Pre-T1 and ECV were poor predictors for CRT response, while Scar2SD and Gray2SD 
were substantially better at predicting CRT response ([AUC: 0.692, p=0.063] and 
[AUC: 0.759, p=0.012] respectively). QRSarea, but not Tarea or QRSd, significantly 
predicted CRT response (AUC: 0.737, p=0.022) (see Table 13 and Figure 35). 
 
Table 13- ROC analyses predicting CRT response for CMR and VCG parameters 
 	 	 AUC	 CI	 p-value	 Threshold	 Sensitivity	 Specificity	T1	mapping	(diffuse	fibrosis)		 	 	 	 		 Pre-T1	(ms)	 0.461	 0.258-0.663	 0.702	 <1063	 47%	 50%		 ECV	(%)	 0.650	 0.455-0.846	 0.145	 <0.32	 68%	 72%		 	 	 	 	 	 	 	LGE-CMR	(focal	scar)	 	 	 	 		 Gray2SD	(%)	 0.759	 0.586-0.933	 0.012*	 <5.91	 74%	 71%		 Scar2SD	(%)	 0.692	 0.503-0.881	 0.063	 <20.29	 68%	 72%		 	 	 	 	 	 	 	VCG		 	 	 	 	 	 		 QRSd	(ms)	 0.635	 0.438-0.832	 0.190	 >148	 63%	 57%		 QRSarea	(mV.ms)	 0.737	 0.564-0.910	 0.022*	 >66	 74%	 71%		 Tarea	(mV.ms)	 0.560	 0.358-0.762	 0.560	 >39	 63%	 50%	








Figure 35- ROC analyses predicting CRT response (∆LVESV ≥15%) for CMR focal 




4.2.5.4 Combining VCG and Scar parameters 
 
The study population was dichotomized using the cut-off values for Scar2SD, Gray2SD 
and QRSarea derived from the ROC analyses in Table 13. The percentage of CRT 
responders was significantly higher in patients with low Gray2SD and low Scar2SD versus 
patients with high focal scar parameters (Figure 36A). The percentage of CRT response 
was also higher in patients with high QRSarea as compared to those with low QRSarea 
(Figure 36B).  
 
Crosstab analyses between QRSarea and Gray2SD or Scar2SD showed that the percentage 
CRT response was highest (92%) in patients with a combination of low Gray2SD 
(≤5.91% LV mass) or low Scar2SD (≤20.29% LV mass) and high QRSarea (>66 mV.ms). 
The four subgroups in Scar2SD+QRSarea combinations differed significantly from each 
other (overall: p<0.001; Figure 36C). For Gray2SD+QRSarea combinations, although the 
overall group comparison did not reach a significant level (overall: p-value =0.088), 
there is a significant difference between the subgroup [low Gray2SD+high QRSarea] when 
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compared with the other subgroups; there is no significant differences between the 




2D bar graphs showing CRT response percentage per focal scar CMR (A) and VCG (B) parameter when 
dividing the study population using the cut-off value as determined by ROC analyses. P-values in A and B 
are based on Chi-squared tests.   
3D bar graphs demonstrating CRT response percentage when combining QRSarea with focal scar CMR 








The present study is the first to investigate the relationship between VCG parameters 
and CMR defined scar, and between these parameters and CRT response. The principal 
findings of this study are:  
 
1) QRSarea, but not QRSd or Tarea, significantly correlated inversely with focal scar, 
suggesting that myocardial scar leads to a smaller QRSarea 
 
2) combining QRSarea and CMR focal scar assessment improves the prediction of CRT 
response beyond that by either VCG or scar parameters alone particularly identifying a 
cohort very likely to respond. 
 
4.2.6.1 The role of VCG in clinical context 
 
The VCG technique was first described almost a century ago. VCG measures the 
electrical activity of the heart as a vector loop consisting of momentary magnitudes and 
directions in 3D space for each time point in the heart cycle. Various VCG systems 
have been introduced, from which the Frank VCG system (employing seven recording 
electrodes) was the most common VCG system in clinical care in the 1960s together 
with the current 12-lead ECG system.83 After a period of discontinuation in clinical 
practice, interest in the use of VCG regained in the late 1980s, and mathematical 
matrices were developed to synthesize the VCG from the 12-lead ECG.165 Advantages 
of VCG parameters over the 12-lead ECG-derived morphology definitions (like LBBB) 
is that VCG parameters are objective continuous parameters and therefore more suitable 
for statistical analyses. QRSarea and Tarea defined as the 3D integral of the QRS- and T-
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wave loop respectively, resemble dispersion of depolarization and repolarization, and 
are the most common VCG parameters recently investigated in CRT.163,166-168  
 
4.2.6.2 The association between VCG and CMR scar 
 
The usefulness of VCG for identification of myocardial scar has been investigated by 
Bizarro et al. almost four decades ago.169 In this small study, automatically generated 
VCG parameters from both the QRS- and T-  loop were able to identify 85% of the 
patients with autopsy-confirmed scar. Ever since, the majority of studies have focused 
on comparing features from the 12-lead ECG with myocardial scar.170,171 However, the 
use of these ECG criteria in estimating scar extent is complex and particularly debatable 
in patients ventricular conduction disturbances.171 
  
In the present study, correlation analyses suggested that QRSarea decreased with focal 
scar burden (encompassing dense scar core), and to a lesser extent scar border zone; but 
VCG parameters were not significantly associated with measures of diffuse fibrosis. 
This suggests that scar tissue with higher density affects the VCG 3D loop the most.   
 
A low QRSarea theoretically resembles less dispersion and subsequently a small amount 
of unopposed forces during ventricular depolarization. The size of these forces likely 
depends on the uniformity of slow conduction and the amount of viable myocardium. A 
lower number of viable myocardial cells, lateralization of connexins, and increased 
axial resistivity after myocardial infarction may lead to a decrease of total electrical 
forces during the cardiac cycle and therefore an overall decrease of VCG amplitude, and 
subsequently low QRSarea and Tarea.  
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QRSarea is not only affected by the severity of focal myocardial scar, but may also be 
affected by the etiology of heart failure alone. Van Deursen et al. reported lower QRSarea 
in patients with ischemic cardiomyopathy compared to patients with non-ischemic 
cardiomyopathy.163  
 
Interestingly, patients with higher percentages of focal scar had lower QRSd. This may 
be explained by the fact that our study population consists of patients with ventricular 
conduction disturbances (a prerequisite for CRT implantation) that intrinsically, even in 
the absence of scar, already prolongs QRSd.  
 
4.2.6.3 The role of VCG in CRT response prediction 
 
The significant association of a large QRSarea with more LV reverse remodeling after 
CRT is in line with earlier studies demonstrating a significant association of QRSarea 
with CRT response.163,172 QRSarea has been shown to be associated with delayed 
electrical activation on the LV lateral wall.172 QRSarea represented unopposed 
ventricular contraction forces. A larger QRSarea therefore reflected a greater degree of 
ventricular electrical dyssynchrony which   is   amenable to CRT.39,163 
 
The strength of QRSarea in predicting CRT response is particularly demonstrated in a 
recent multicentre prospective study by Maass et al. where numerous clinical, 
echocardiographic, blood, and electrocardiographic biomarkers were studied and related 
to LV reverse remodeling.166 From all these biomarkers, only QRSarea and 
echocardiographic interventricular mechanical delay and apical rocking remained 
significantly associated with LV reverse remodeling in the multivariate model. 
Although Tarea in their data initially showed a strong significant association in the 
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unadjusted model with LV reverse remodeling (p-value <0.0001), significance was not 
preserved in the multivariate model.166 Interestingly, Tarea proved to predict CRT 
response better than QRSarea in retrospective studies by Engels and Vegh et al. The fact 
that QRSarea outperformed Tarea in both the Maass and the present study indicates that a 
potential role for Tarea in CRT response prediction is not fully understood yet.85,168  
 
4.2.6.4 The relevance of myocardial scar regarding CRT response 
 
The association between focal scar burden and poor CRT response has been 
investigated in numerous studies.78,94,164 Chalil et al. demonstrated that CRT recipients 
with a scar size of <33% showed significantly more favorable clinical response to 
patients with ≥33% scar. Patients with a posterolateral scar, the common site for LV 
lead placement, also had a higher risk of cardiovascular death and HF hospitalization. 
Leyva et al. concordantly studied the use of LGE to guide LV lead placement remote 
from scar tissue in a large cohort of 559 patients. In their data, patients with LGE 
confirmed scar showed the highest risk of cardiovascular death and lowest 
echocardiographic CRT response, confirming the importance of pacing remote from 
scar.164  
 
After the introduction of T1 mapping in CMR, a few studies additionally investigated 
the potential role of diffuse fibrosis in CRT response.76,173 The association between 
diffuse fibrosis and focal scar and LV reverse remodeling was studied by Chen et al. 
prospectively in CRT candidates with ischemic and non-ischemic etiologies of HF. In a 
multivariate model only focal scar burden, but not diffuse fibrosis, was able to predict 
LV reverse remodeling significantly.  Höke et al investigated the association of diffuse 
fibrosis with CRT response prediction specifically in the non-ischemic cohort.173 In 
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their data both focal scar as well as diffuse fibrosis were associated with LV reverse 
remodeling after CRT. These findings indicate that diffuse fibrosis may have a potential 
role in CRT response prediction in patients with non-ischemic cardiomyopathy.  
 
4.2.6.5 Combining VCG with CMR for a better CRT response prediction 
 
The present study demonstrates that combining parameters reflecting both electrical and 
tissue substrate for CRT may be an accessible approach to further improve CRT 
response prediction. Almost all (92%) patients with a low extent of focal scar and a 
large QRSarea were CRT responders. This finding is important, since myocardial scar 
burden and QRSarea are inversely related to each other. Apparently, the negative effect of 
scar on CRT response is stronger than that on QRSarea alone. Potential explanations for 
this observation may be that 1) scar reduces the amount of resynchronization, 2) pacing 
in scar may even further reduce resynchronization and 3) pacing in scar has been shown 
to be pro-arrhythmic.174  
 
4.2.6.6 Clinical Implications 
 
The present study supports earlier findings that QRSarea may improve the selection of 
CRT candidates and extends this idea by demonstrating that further improvement in 
selection may be obtained by combining scar characterization using CMR and VCG 
analysis. The refined positive predictive value using such combined VCG-CMR focal 
scar index is highly encouraging, in particular in the ischemic cardiomyopathy cohort, 






This study incorporated a relative small number of patients from a single center with the 
inherent limitation of such study design. Nevertheless, the consecutive patient’s cohort 
reflects a broad real-world experience. The optimal thresholding values for the scar 
VCG parameters should be taken in the context of the study and a larger population 
study is needed to validate these optimal thresholding values and different cut-offs may 




Focal scar CMR parameters and QRSarea are independent predictors for CRT response 
and are inversely associated with each other. The highest percentage of CRT response 
was observed in patients with low focal scar CMR values and high QRSarea, indicating 


















Chapter 5 COST-EFFECTIVENESS OF A RISK-STRATIFIED 
APPROACH TO CARDIAC RESYNCHRONISATION THERAPY 
DEFIBRILLATORS AT THE TIME OF GENERATOR CHANGE 
 
5.1  Abstract 
Objective: 
Responders to cardiac resynchronisation therapy whose device has a defibrillator 
component and who do not receive a therapy in the lifetime of the first generator have a 
very low incidence of appropriate therapy after box change.  We investigated the cost 
implications of using a risk stratification tool at the time of generator change resulting 
in these patients being reimplanted with a resynchronisation pacemaker. 
 
Methods: 
A decision tree was created using previously published data which had demonstrated an 
annualised appropriate defibrillator therapy risk of 2.33%.  Costs were calculated at 
National Health Service national tariff rates (2016-2017). EQ-5D utility values were 
applied to device re-implantations, admissions and mortality data, which were then used 
to estimate quality-adjusted life-years over 5 years. 
 
Results: 
At 5 years, the incremental cost of replacing a resynchronisation defibrillator device 
with a second resynchronisation defibrillator vs resynchronisation pacemaker was 
£5,045 per patient. Incremental quality adjusted life-years gained was 0.0165 
(defibrillator vs pacemaker), resulting in an incremental cost effectiveness ratio of 
£305,712 per quality adjusted life-years gained. Probabilistic sensitivity analysis 
resulted in an incremental cost effectiveness ratio of £313,612 (defibrillator vs 
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pacemaker). For re-implantation of all patients with a defibrillator rather than a 
pacemaker to yield an incremental cost effectiveness ratio of less than £30,000 per 
QALY gained (current NHS cut-off for approval of treatment), the annual arrhythmic 
event rate would need to be 9.3%.  The budget impact of selective replacement was a 
saving of £2,133,985 per year. 
 
Conclusions: 
Implanting low risk patients with a resynchronisation defibrillator with the same device 
at the time of generator change is not cost-effective by current NHS criteria. Further 
research is required to understand the impact of these findings on individual patients at 
the time of generator change. 
 
5.2 Introduction 
Cardiac resynchronisation therapy both with and without a defibrillator is a proven and 
cost effective treatment for symptomatic patients with left ventricular dysfunction and 
prolonged QRS duration. [10,175-177] However, there has been no statistically powered 
direct comparison of cardiac resynchronisation therapy with a defibrillator (CRTD) and 
without a defibrillator (CRTP).[177] Furthermore, there is minimal evidence to support 
the continuation of defibrillator therapy in patients with a primary prevention device 
who have not received appropriate therapy during the lifetime of the initial device.  
Registry data suggest that the risk of appropriate therapy following generator change 
may be as high as 25% at 5 years in an unselected cohort of patients implanted with 
both primary and secondary prevention defibrillators who did not receive appropriate 
therapy during the initial generator lifetime.178  However, patients with a primary 
prevention ICD whose left ventricular (LV) ejection fraction has improved and who 
have not received an appropriate therapy have been shown to have a much lower risk of 
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subsequent appropriate therapy (2.8% per year).179   The risk of appropriate therapy in 
patients responding to CRT may be further reduced due to LV improvement.  In 
keeping with this we have previously demonstrated a low rate of appropriate therapy 
following generator replacement (2.33% per annum) in patients who had received 
primary prevention CRTD implantation with positive remodelling that had not received 
appropriate therapy during the lifetime of the initial device.180 This figure is nearly 
identical to that published in a meta-analysis which estimated a 2.3/100 patient-year rate 
of appropriate therapy in CRT responders with a remodelled ejection fraction of >45%. 
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In the United Kingdom, a need to save £22 billion per year by 2020/21 has been 
identified by NHS England requiring ongoing assessment of both the cost-effectiveness 
and budget impact of treatment options.117 We therefore set out to determine the cost-
effectiveness and budget impact of replacing an end of life CRTD generator with either 
CRTD or CRTP in patients who initially received a primary prevention CRTD for heart 
failure, required an elective generator replacement and had no theoretical ongoing ICD 
indication (TOII).  TOII was defined as patients with a left ventricular ejection fraction 















TTE = trans-thoracic echocardiogram, clinic = out-patient clinic visit, Arr event = 
arrhythmic event occurring after generator replacement.  Device interrogation, TTE 
and the first clinic visit occur in year 1 only, ie prior to elective generator replacement.  
Arrhythmic events and upgrade of CRTP to CRTD occur annually thereafter and were 
modelled out to five years. 
Device interrogation, trans-thoracic echocardiogram (TTE) and the first clinic visit were 
modelled to occur in year 1 only, i.e prior to elective generator replacement and for all 
patients, regardless of the final device replacement choice.  Arrhythmic events and 
upgrade of CRTP to CRTD were modelled to occur annually thereafter and out to five 
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years.  Modelling was not pursued beyond five years as this was considered to be 
outside the scope of current NHS budget consideration and would introduce the 
additional complexity of further generator replacement.  The base case model was 
deterministic, i.e data were input as single values.  A probabilistic analysis i.e data input 
as distributions, was also undertaken and is detailed below.   
Furthermore, the overall budget impact was assessed to estimate the financial 
consequences.  The overall percentage of CRTD devices replaced in England was 
estimated from the pacemaker and ICD replacement rates reported in the latest available 
cardiac device audit.182   This was then applied to the reported total number of CRTD 
implantations to estimate the annual number of CRTD implantations that were generator 
replacement procedures. 
 
5.3.1 Clinical Events 
 
Clinical event rates used in the model are shown on Figure 37.  An arrhythmic event rate 
of 2.33% per year was derived from the data reported by Sebag et al.180 This was a 
critical input and is the annualised arrhythmic event rate calculated from the observation 
of Sebag et al, that 2/39 patients without TOII suffered an arrhythmic event over 26.4 
months of follow up after first generator replacement.  In patients modelled to be 
implanted with CRTP at first generator replacement, 50% mortality was assumed to 
result from an arrhythmic event, although this was varied in sensitivity analysis.  
Survivors in the CRTP arm were then modelled to require a further out-patient visit and 
upgrade to a CRTD.  Therefore, the base case scenario for patients implanted with 
CRTP at first generator replacement included an annual probability of death of 0.0117 
and an annual probability of out-patient visit followed by upgrade to CRTD of 0.0117. 
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The alternative scenario of CRTD implantation at first generator replacement was 
assumed to reduce the rate of arrhythmic death by 19%, (although this was varied in 
sensitivity analysis).183 This therefore reduced the annual probability of arrhythmic 
death for patient receiving CRTD at first generator replacement in the base case to 
0.0094 and increased the annual probability of a further out-patient visit to 0.0139, 
maintaining an overall annual arrhythmic event probability of 0.0233.  Patients in this 
arm of the model had zero probability of upgrade to CRTD as this type of device would 
have been implanted at the first generator replacement. 
5.3.2 Quality-adjusted life years 
 
Expression of outcomes in terms of quality-adjusted life years (QALYs) allows a cost to 
be applied to compare healthcare interventions in a common currency.  The EQ-5D 
questionnaire is used to determine utility values that can then be converted into QALYs. 
This approach, using a standard part of NICE’s methodology has been successfully 
adopted in previous cost effective analyses.183,184 Results are commonly expressed as an 
incremental cost effectiveness ratio (ICER), which is a division of the additional cost of 
the treatment option by the incremental QALYs gained by employing that option.  An 
ICER of £20,000 to £30,000 per QALY gained is the range in which cost effectiveness 
is acceptable in terms of NHS resource use and this range was considered applicable to 
the current evaluation. 
 
The QALY losses used in the model are shown in Table 14.  Mortality and CRTD 
implantation after an arrhythmic event used to calculate QALY differences between the 
two generator replacement options.  A baseline utility of 0.8708 was used for a patient 
with CRT.  This was derived from the utility of 0.78 for a patient aged 66, plus the 
utility gain of 0.0908, associated with the use of CRT. The QALY loss due to death was 
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taken as the fall from 0.8708 to zero.  The QALY loss due to an upgrade from CRTP to 
CRTD was calculated to be 0.0036.  Upgrade to CRTD was assumed to incur the same 
QALY loss as a heart failure admission.  The utility for a heart failure admission was 
calculated, from the work of Swinburn et al and Lewis et al, to be 0.1197.185  This was 
taken to persist for 11 days, which is the mean length of stay for a heart failure 
admission. 
 
Table 14- Event probabilities and utility values used in the economic model 
 
Description Model input Standard Error Distribution Source 
Annual probability of death with 
CRTP 
0.0117 0.0172 Beta Sebag et al  
Annual probability of out-patient 
attendance following survival of 
arrhythmic event 
0.0117 0.0172 Beta Sebag et al  
Annual probability of upgrade of 
CRTP to CRTD following 
survival of arrhythmic event 
0.0117 0.0172 Beta Sebag et al  
Proportion of CRTP patients 
dying as a result of arrhythmic 
event 





Relative risk of death for CRTD 
vs CRTP 
0.81 0.09 Beta Woods et al  
Baseline QALY for patient with 
CRT 
0.8707 0.0118 Beta Kind  
QALY loss associated with 
arrhythmic event and CRTD 
implantation 
0.0036 0.0036 Beta Swinburn et 
al, 






National tariff costs for England for the year 2016-17 were applied to device 
interrogation, trans-thoracic echocardiogram, out-patient visit and CRTP implantation.  
CRTD replacement and upgrade from a CRTP to CRTD (CRTD complete system 
implantation) was costed according to the methodology used to inform NICE’s 2014 
Technology Appraisal – i.e a device cost plus the tariff price.  The CRTD device cost 
was taken from the same NICE appraisal and assumed to be unchanged since that time.  
Where there were different tariff values for complication/co-morbidity splits, averages 
weighted by the number of admissions for each were calculated.  The base tariff price 
was multiplied by the market forces factor (local cost factor) for the hospitals 
implanting CRT devices, and the mean of these values were used in the model.  The 
cost for a CRTD generator and CRTD whole system were not multiplied by market 
forces factors.  Costs used in the model are shown on Table 15 
 
Table 15- Costs used in the economic model 
 
Description Mean Cost (£) Std Error Distribution Source 





£73 £0.53 Gamma HRG RA60A, simple 




£104 £0.75 Gamma TFC 320, follow up 
attendance, single 
professional 
CRTD generator £2,560 £19 Gamma HRG EA39Z, pacemaker 
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£11,752 - Fixed 14 
CRTD implantation 
procedure 
£6,735 £49 Gamma HRG EA56Z, implantation 
of cardiac resynchronisation 
therapy defibrillator. 
CRTD whole system £12,293 - Fixed 14 
CRTP implantation £8,233 £60 Gamma HRG EA07Z, Pace 3 - 




Arrhythmic death £76 £0.55 Gamma HRG VB09Z, emergency 
medicine, category 1 
investigation with category 
1-2 treatment (average of 
two tariffs) 
 
These costs are the average of national tariff costs multiplied by the market forces factor (ie local cost 
factors) for each hospital that implants CRT devices. 
5.3.4 Sensitivity analyses 
 
Inputs to the base case model were varied to their upper and lower 95% confidence 
intervals in order to determine which factors had most impact.  In addition, a 
probabilistic sensitivity analysis (PSA) was also undertaken, in which most data were 
input not as fixed values, but as distributions.  The annual arrhythmic event rate was 
also varied in a threshold analysis to determine what the annual arrhythmic event rate 







In the base case analysis at 5 years, the incremental cost of replacing a CRTD device 
with a second CRTD in a patient with no TOII was £5,045.  Incremental QALYs 
gained was 0.0165, resulting in an ICER of £305,712 per QALY gained.  Although 
elective generator replacement with a second CRTD device improved outcome 
(resulted in more QALYs), it was notably more costly and the cost per QALY gained 
was well above range normally considered to be cost-effective (£20,000 per QALY 
gained).186  In this cohort of patients, effective strategy.  Table 16 is a Tornado plot 
showing the impact of varying a number of model inputs to their upper and lower 


















Table 16- Tornado plot showing the impact of separately varying a range of input to 
their upper and lower 95% confidence intervals 
 
 
The inset shows detail of the changes with proportion of CRTP death and relative risk of death with 
CRTD removed.  Hatched bars show the impact of using the lower 95% CI, solid bars show the impact of 
using the upper 95% CI.  Data labels on each bars show the ICER resulting from the change in value.  A 
shift to the right of the centre line shows an ICER that denotes less favourable cost effectiveness than the 
base case.  
 
The proportion of patients dying after an arrhythmic event following generator 
replacement with CRTP and the relative risk of death for CRTD versus CRTP had the 
biggest impact on the results.  By comparison, the costs of device interrogation, TTE, 
out-patient visit and death had no impact on the ICER at 5 years and are therefore not 
shown on the Tornado plot.  None of these variations resulted in an ICER that would 
have made generator replacement with CRTD cost-effective.  PSA resulted in an 
incremental cost of £4,942 and 0.0158 QALYs gained for CRTD versus CRTP, 
resulting in an ICER of £313,612.  PSA also showed that generator replacement with 
CRTD was cost effective in only 2.7% of simulations at £20,000 per QALY gained and 
3.2% of simulations at £30,000 per QALY gained, supporting the view that generator 
replacement with CRTP is most likely to be cost-effective (see Figure 38). 
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Figure 38- Cost effectiveness acceptability curve showing probability that generator 




In order for the CRTD to yield an ICER of less than £30,000 per QALY gained, the 
annual arrhythmic event rate would need to be 9.3% (ICER of £29,613).  In order for 
the CRTD to yield an ICER of less than £20,000 per QALY gained, the annual 
arrhythmic event rate would need to be 10.4% (ICER of £19,929). 
 
The budget impact of selective replacement of CRTD with CRTP in patients with no 
TOII was a saving of £2,133,985 per year for England.  This is based on an estimate of 
1,160 CRTD generator replacements per year (23% of the total CRTD implants), 
multiplied by the proportion of patients with no TOII multiplied by the incremental cost 




































Using a simple clinical risk stratification tool at the time of generator change clearly 
demonstrated a significant cost saving far in excess of that seen with a blanket CRTD 
re-implantation strategy in patients with no theoretical ongoing ICD indication.  Whilst 
an unstratified approach of CRTD generator replacement in all patients might be 
clinically preferable, it is highly unlikely to be cost-effective in the current economic 
climate. These findings would suggest that there is a role for such a risk stratification 
strategy as the health service attempts to increase efficiency in increasingly austere 
times.  By conducting a threshold analysis, we were able to demonstrate that the annual 
arrhythmic risk would have to rise as high as 10.4% for the blanket strategy currently 
employed to be cost effective. 
 
Clearly, cost-effectiveness is not the only consideration at the time of generator change, 
particularly where arrhythmic events may result in death. In the study of Sebag, neither 
of the patient received therapy had shocks but instead had ATP for slow VT.  In order to 
implement this strategy, cardiologists would need to be accepting of a low rate of 
mortality in patients that received a CRTP at generator replacement and this would have 
significant ethical issues which would have to be considered with an individualised 
patient approach.   Lewis et al have recently demonstrated that 83% of patients felt that 
it was “important” or “very important” to discuss the risks and benefits of continued 
therapy with their physician.187  They also found that >50% patients were unaware that 
ICD replacement was not compulsory and that 74% patients over-estimated the 
potential benefits of having a defibrillator. Finally the authors noted that patients 
underestimated the risk of generator replacement including the risks of device infection.  
There is also evidence that cardiologists tend to deny quality of life issues and the long-
term consequences of ICD placement whilst potentially allowing patients to 




Further to the ethical aspects raised, there are potential legal issues to be considered:  As 
with all treatments, we advocate that the risks and benefits of switching to a CRTP 
should be discussed with patients and consent to the small increased arrhythmic risk 
should be sought.  Switching to a CRTP without patient consent based on a general 
policy initiative such as NICE guidance may result in some patients seeking legal 
redress either at the time of generator change or if they have an arrhythmia.  This would 
be a matter of public policy for the Department of Health and would go against our 
favoured patient-centred, individualised approach to risk stratification. 
 
Beyond our risk stratification tool, it may be feasible to further select patients at reduced 
risk of appropriate therapy from a defibrillator. The recent DANISH study failed to 
show a mortality benefit in long-term follow up in non-ischaemic patients with a 
primary prevention defibrillator despite a significant reduction in sudden arrhythmic 
deaths.91  A significant proportion of these patients had CRTD and it is possible that 
these patients represent a lower risk group than a matched ischaemic cohort and may not 
require CRTD at box change. In accordance with this, in the study of Sebag, 67% of 
patients who were eligible for CRTP following risk re-stratification had non-ischaemic 
cardiomyopathy.  Other markers of arrhythmic risk including pre-implant cardiac 
magnetic resonance imaging indices (e.g. T1 mapping and Grayzone) may also be of 
assistance in further refining risk stratification.101 
 
With shrinking resources and increased healthcare requirements, there is a need for 
novel approaches to healthcare delivery which means that cost effectiveness issues need 
to be revisited when significant financial outgoings related to a treatment are 
anticipated.   A treatment that is cost effective in a patient at one time point may cease 
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to be at another as its potential benefit wanes. Our data here reflects one example of this 
but similar analyses need to be undertaken in all areas of medicine to ensure the best 




We used NHS tariff prices rather than reference costs as tariff prices are those paid 
service commissioners to hospitals.   In multiplying the tariff price by the market forces 
factor for each hospital, we have arrived at a monetary value that is actually spent by the 
health service.  This approach also allowed a cost distribution to be used in the PSA. 
 
It could be argued that in a blanket strategy of CRTD implantation in all patients, the 
cost of device interrogation, TTE to determine left ventricular ejection fraction and out-
patient visit may not be required.  However, these costs were shown to not affect the 
ICER and it is likely that an out-patient visit would still be likely before CRTD 
replacement.  If these costs were removed, the cost of ‘CRTD for all’ would reduce by 
£281 per patient.  It would therefore still remain cost-saving to employ a strategy of 
replacing CRTD with CRTP and upgrading to CRTD when an arrhythmic event 
occurred in patients with no TOII.  We have included these costs in the model in order 
to determine the complete cost of the risk stratification strategy. 
 
We are unable to include in our analysis any potential psychological harm that may 
come to patients if they were risk re-stratified to CRTP against their will.  As noted 
above, there is a significant lack of clarity amongst patients over the benefit accrued 
from ICD insertion and it is contended that this psychological harm may be obviated to 
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a large degree with proper consultation.  Nonetheless it is accepted that for a proportion 
of patients this strategy would be unacceptable.   
 
Recent NICE guidance has recommended the use of specific CRTD devices due to 
potential prolonged battery life. This would likely reduce the number of patients 
surviving to box change.  However, it is feasible that those who fulfil our risk 
stratification criteria for CRTP at 9 years are at an even lower risk of sudden arrhythmic 
death making the decision to switch to CRTP less contentious and economically even 
more desirable.  Further research is required to investigate this cohort.  It should also be 
noted that it is unlikely that all patients will be offered a single manufacturer’s devices 
as it is common practise to buy devices from several manufacturers to minimise the risk 
associated with potential product malfunctions. 
 
5.6.1 Practical considerations in switching from CRTD to CRTP 
 
From a practical perspective, many CRTD generators now have a DF4 adaptor.  Whilst 
a DF1-CRTD can be changed to a CRTP with ease, there are currently no adaptors 
available to plug a DF4 lead into an IS1 port.  These patients would require a new right 
ventricular lead to receive CRTP.  There are added risks associated with lead insertion 
and these would have to be factored into the decision-making process.   It should be 
noted, however, that there are many different adaptors on the market which have been 
designed to overcome previous issues with device/ lead incompatibility; there is no 
specific reason why a DF4 to IS1 adaptor could not be manufactured. 
 
Finally, the CRTP generator typically has a significantly smaller volume than a CRTD 
generator.  This is potentially attractive at the time of generator change as patients often 
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get thinner as they age making a less bulky device preferable.  This could potentially 




The QALY cost and ICER of replacing CRTD generators with a second CRTD device 
in patients without TOII at the time of generator change when compared with the use of 
a simple risk re-stratification tool which results in patients potentially receiving either 
CRTD or CRTP is far in excess of therapies that would be standardly approved by 
NICE. However, this re-assessment of the need for a potentially lifesaving treatment is 
novel, potentially controversial and thus requires an individualised patient–centred 











Chapter 6 SYNTHESIS OF STUDIES, DISCUSSION AND 
CONCLUSION 
6.1 Synthesis and discussion 
 
I have attempted in this thesis and during the period of study to examine different 
questions relating to complex cardiac implantable electronic devices.  The research 
presented here represents a snapshot of many ongoing projects in which I am still 
actively involved. Through the invasive haemodynamic studies described in chapter 3 I 
have investigated elements of the basic physiology that underpins why and how these 
devices work.  In chapter 4, I have sought to determine novel strategies by which 
patients may be risk-stratified and in future possibly even selected as to whether they 
are suitable candidates for CRT or ICD devices using both CMR and VCG. These 
experiments have shed new light on the interaction of the surface electrocardiographic 
data with the structural changes observed using CMR. Finally, I have examined the 
need for and, primarily, cost -effectiveness of ongoing provision of defibrillators in low 
risk groups at the time of generator change.   
 
Through these experiments several new insights have been described. 
 
• Whilst endocardial pacing increases coronary flow minimally, there are large 
increases in both the forward compression wave and backward expansion wave.  
However it appears that changes in contractility drive the changes in flow and 
wave intensity rather than vice versa.  The changes in wave intensity and 
coronary flow are in effect a passive phenomenon rather than the driving force 




• T1 mapping is a powerful marker in the prediction of VA in patients with NCM. 
Grayzone predicts VA in the ICM population.  The specificity of these findings 
by aetiology is biologically plausible and this is the first description of potential 
substrate base risk stratification 
 
• Fragmentation of QRS is a measure of scar-core and did not predict arrhythmic 
risk in our ICD population regardless of aetiology.  
 
• QRSarea as measured by VCG is inversely correlated with scar burden as 
measured by CMR and both predict response to CRT.  This is the first described 
investigation of the relationship between VCG and CMR indices 
 
• Replacing all CRTD generators on a like for like basis is not cost-effective in the 
NHS.  Use of a simple clinical tool to risk stratify patients at the time of 
generator change could result in significant healthcare savings without 
significant harm. 
 
6.2  Future research directions 
 
The role of CMR to risk stratify ICD patients needs to be evaluated in a prospective, 
randomised clinical trial particularly in a NCM cohort using T1 mapping where the cut-
offs used in Chapter 4 resulted in a very low risk of VA.  The need for this study is 
further highlighted by the recent DANISH study where at 7 years device therapy failed 
to improve survival of all-comers (NCM).91 The study did however show benefit to ICD 
implantation at approximately 4 years and it may be that CMR helps to identify a higher 
risk cohort in whom ICD implantation may be of benefit.   At the moment such studies 
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are hindered by the variation in scanners making the use of cut-off values difficult to 
incorporate into multi-centre studies. 
 
Further research is required into the relationship between VCG metrics (QRSarea, 
Twavearea ) and CMR specifically with reference to the ICD population and VA.  I hope 
to be involved with future projects in this field. 
 
Whilst implanting a CRTP rather than a CRTD may be financially prudent and 
clinically acceptable, further research is required into the acceptability of these 
strategies to physicians and patients.   I am currently overseeing an MSc project 
investigating the view of physicians on these decisions. 
 
Finally, there is a need for ongoing research to understand the physiological response to 
CRT, to determine whether it is possible to better select patients for this treatment or 
whether it is indeed possible to turn non-responders into responders.  The studies 
presented here suggest that future studies should investigate the role of myocardial scar 
and other parts of the cascade of heart failure describe above rather than the coronary 
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